Published in final edited form as:

Cell Mol Life Sci. 2015 May ; 72(10): 1863–1879. doi:10.1007/s00018-015-1839-9.

Cellular factors modulating the mechanism of tau protein aggregation

Sarah N. Fontaine, Jonathan J. Sabbagh, Jeremy Baker, Carlos R. Martinez-Licha, April Darling, and Chad A. Dickey

Department of Molecular Medicine, College of Medicine, Byrd Alzheimer's Institute, University of South Florida, Tampa, FL 33613, USA

Chad A. Dickey: cdickey@health.usf.edu

Abstract

Pathological accumulation of the microtubule-associated protein tau, in the form of neurofibrillary tangles, is a major hallmark of Alzheimer's disease, the most prevalent neurodegenerative condition worldwide. In addition to Alzheimer's disease, a number of neurodegenerative diseases, called tauopathies, are characterized by the accumulation of aggregated tau in a variety of brain regions. While tau normally plays an important role in stabilizing the microtubule network of the cytoskeleton, its dissociation from microtubules and eventual aggregation into pathological deposits is an area of intense focus for therapeutic development. Here we discuss the known cellular factors that affect tau aggregation, from post-translational modifications to molecular chaperones.

Keywords

Tau; Alzheimer's disease; Tauopathy; Aggregation

Introduction

A major hallmark of a number of neurodegenerative diseases is accumulation of the microtubule (MT)-associated protein tau. Though tau was initially identified as a component of the pathological neurofibrillary tangles associated with Alzheimer's disease (AD) [1], several neurodegenerative disorders present tau pathology in the absence of amyloid pathology. There are a number of these tauopathies, including AD, frontotemporal dementia with parkinsonism associated with chromosome 17 (FTD-17), corticobasal degeneration (CBD), Pick's disease, chronic traumatic encephalopathy (CTE), argyrophilic grain disease, and progressive supranuclear palsy (PSP). Genetic analyses of non-AD tauopathies revealed these patients possessed missense, silent and deletion mutations in the *MAPT* gene; in familial FTD-17 alone over 40 different *MAPT* mutations have been reported, as reviewed in [2]. The identification of these mutations, in addition to broader understanding of the

genetics of neurodegenerative disorders, has implications for the analysis of mechanisms of tau aggregation and function in vitro.

Thorough immunohistochemical analyses using conformational epitope antibodies, as well as biochemical and electron microscopy assessments performed on post-mortem tissue, indicate tau accumulations that are present in both neuronal and glial cells with a wide variety of morphologies and distribution patterns for the different tauopathies [3–11]. Here, we review what is known about cellular factors that influence the mechanism of tau aggregation to define potential areas for therapeutic intervention across these differing tauopathies.

Tau structure and function

The tau protein is an intrinsically disordered protein encoded by a single gene (*MAPT*) residing on chromosome 17q21 in humans [12]. The protein is robustly expressed in neuronal axons in the central nervous system (CNS), while evidence exists for expression in additional CNS cell types [13]. In humans, tau mRNA is alternatively spliced resulting in the presence or absence of three regions encoded by exon 2, exon 3 and exon 10, yielding six distinct isoforms of tau [14]. Alternative splicing of exon 10 results in tau with either 3 or 4 MT-binding repeats, both of which are found in tangles in the brains of tauopathy patients [15, 16].

MAPT mutations associated with inherited tauopathies largely can be classed into two categories: those which are solely impactful at the protein level or those that affect mRNA splicing, resulting in increased production of 4R tau. Further, several mutations located in exon 10 can have effects at both protein and RNA levels [17] (Table 1).

Recombinant tau protein can be readily produced in *E. coli*, allowing for a wide array of biochemical and biophysical assessments on the protein, furthering the study of tau biology [46, 80–84]. Tau contains multiple domains including an acidic N-terminal domain, a central proline-rich region, a predominantly basic repeat region responsible for binding to MTs, and a C-terminal domain comprised of mostly neutral residues. The tau repeat domain contains 3 or 4 repeats, depending on splicing of exon 10, and each repeat domain contains a KXGS consensus site. Phosphorylation of the serine in these motifs disrupts tau binding to the MT and serves to regulate tau-mediated MT assembly [85]. In solution, a variety of spectroscopic techniques including circular dichroism (CD), Fourier transform infrared (FTIR) and nuclear magnetic resonance (NMR) spectroscopy have shown both brain-derived and recombinant purified full-length tau lacks secondary and tertiary structure and is therefore classed as an intrinsically disordered protein (IDP) [86, 87]. The tau protein consists of several charged residues (~29 % of the residues are charged) yet uniquely for an IDP, has a low net charge of +2 and is not significantly hydrophobic [88, 89]. These distinctive properties of tau protect the protein structure from chemical alterations of its immediate surroundings, including changes in ionic environment, pH, and denaturation [88]. Despite the absence of globular structure, tau is still able to form long-range self-contacts as evidenced by the successful development of conformational epitope antibodies [90, 91].

FTIR and NMR measurements indicate that tau can adopt conformations wherein both termini are folded to be in proximity to the MT repeat region [92–94].

From a functional viewpoint, the first reports of tau indicate it functions to promote MT assembly [95]. Currently, this predominant function of tau in cytoskeletal regulation is widely accepted: tau has high affinity for MTs [96], and upon binding to the MT via the MT repeat regions, stabilizes the MTs at the plus end, providing stability to the MTs during growth phases, while the N-terminal domain of tau may serve as a “spacer” between MTs to ensure adequate distance between them [97–100]. Further, a significant amount of evidence corroborates the MT-stabilizing and assembly enhancing function of tau, as tauopathy-related tau mutations alter the tau-MT association. Several mutations such as P301L, P301S, G272V, L315R, G335V, V337M, R406W, and K280 result in tau being less able to interact with the MT, resulting in reduced MT assembly [67, 81, 98, 101–103]. This might be due to alterations in the functional phosphorylation/dephosphorylation balance necessary for helping to control tau-MT interactions as these mutations have been shown to have differential phosphorylation patterns [21, 63], as well as alteration in the local domain structure of the MT-binding site. Two identified missense mutations, N279K and S305N, do not reduce tau-MT interactions but do lead to increased splicing of exon 10, which is known to affect this interaction [104]. Expression of the recently described FTD mutation G55R in recombinant 4R tau results in enhanced MT assembly, though this is not the case when this mutation is expressed on a 3R tau background [105].

In addition to a key role in regulation of the MT network, tau can interact with the plasma and membrane via adaptor proteins [106, 107] and functions in cargo transport in a MT-independent fashion, through kinesin motors [108]. Several mutations in 4R tau (N296, P301L, R406W) result in altered kinesin-motor transport in vitro when compared to 4R WT tau [109] and it is reported that some tau mutations result in impaired axonal mitochondrial transport [110, 111]. Tau can also be found localized in the nucleus [112], bound to AT-rich polynucleotide sequences and has been reported to protect DNA from stress-induced damage [113] and function in nucleolar organization [114].

New insights into how an IDP can adopt a highly aggregated conformation are more readily available as biophysical methods to assess protein aggregation structure and mechanism become more sensitive. Primary methods of biochemically assessing tau aggregation in vitro rely on using light-scattering [115] and amyloid fibril structure-sensing dyes, such as Congo Red, and thioflavin T or S dyes for kinetic analyses [80–83, 116], and electron microscopy and atomic force microscopy for gross aggregate morphology measurements [117, 118]. More sensitive methods such as NMR and X-ray scattering yield higher resolution data, and have highlighted key structural features required for forming the fibril core down to the specific peptide [119–121]. For more information regarding the biochemical mechanism of tau aggregation, a detailed review of the biochemistry of tau aggregation was recently published [122].

In vitro, recombinant tau aggregation can be initiated using polyanions like heparin, heparan sulfate, tRNA, and polyglutamate [123–126] fatty acids such as arachidonic acid and docosahexaenoic acid [123, 125, 127, 128], and treating either sequentially or with a mixture

of purified kinases [129, 130]. Recent evidence indicates heparin binding to tau may facilitate a conformational transition by simultaneously diminishing long-range contacts and compacting the MT-binding region, resulting in a conformation of tau with higher propensity for aggregation [94]. When isolated, specific domains of tau can adopt distinct secondary structure and conformations, which may correlate to their propensity for aggregation [94, 131, 132]. Isolated modeling and analysis of the K18 peptide (spanning all 4 MT repeats) and K19 (peptide spanning 3 MT repeats) revealed these peptides contain a mixture of ordered and disordered structures including β -sheet-prone structures which may serve as a core or seed for full-length tau aggregation [133, 134]. Toward that end, minimal fibrillation domains have been determined in vitro, primarily within the MT repeat region: amino acids 317–335, 391–407 [135], 275–280, 306–311 [83], and 314–320 [136]. When the MT repeat region is flanked by the C-terminal domain, tau aggregation is reduced [129, 136]. Together, it seems the residues within the MT repeat region are important not only for tau function but also instrumental in the initiation of tau aggregation.

Cellular factors influencing tau aggregation

Among cellular factors which have been reported to affect tau aggregation, we will discuss post-translational modifications (PTMs) (Fig. 1) including phosphorylation, acetylation, and proteolysis, as well as the molecular chaperone machinery..

Post-translational modifications

Phosphorylation

The longest isoform of human tau contains 79 serine/threonine residues along the 441 amino acid stretch (Fig. 1). Of these residues, 20 different sites have been reported to correlate with tau function [137]. Generally, it is thought that tau is phosphorylated and dephosphorylated as a regulatory mechanism to control the association of tau with the MT: tau de-phosphorylation promotes MT binding whereas phosphorylation decreases the affinity of tau for tubulin and stimulates the activity of tau phosphatases, facilitating the disassociation of tau from the MT [138–140]. This theory is supported by the finding that physiological tau can be phosphorylated at residues S199, S202, T231, S262 and S404 in normal adult brain [141]. It may be possible that the multi-site phosphorylation status of tau can confer ultra-sensitivity to the molecule, priming tau for a multitude of responses from interacting proteins [142, 143]. In this way, hyperphosphorylated tau found in diseases could be indicative of an inability of tau to respond correctly to a stimulus, such that tau becomes trapped in a state that is conducive to eventual misfolding and aggregation.

There are three classes of kinases which have been shown to phosphorylate tau, the first of which contains proline-directed kinases such as glycogen synthase kinase-3 (GSK3) [144], mitogen-activated protein kinases (MAPKs) such as ERK1/2, JNK and p38, and cyclin-dependent protein kinase-5. The second class of kinases consists of non-proline-directed kinases such as tau-tubulin kinase, microtubule affinity-regulating kinases (MARKs), casein kinase, and dual-specificity tyrosine phosphorylation-regulated kinase 1A/2 (DYRK 1A/2). The final class of kinases which affect tau is tyrosine protein kinases such as Src family kinases and c-Abl (c-Abl) kinases, which may play a role in tau aggregation as tyrosine-

phosphorylated tau is found in tau aggregates in both transgenic mouse models and AD patient brains [145]. These kinases (and others), their effects on tau, and their suitability as drug targets have been extensively reviewed previously [146–148].

In most tauopathies, pathological tau is hyperphosphorylated at serine/threonine residues [1, 149], particularly within KXGS motifs in the MT-binding region [150]. This suggests a mechanism where excessive hyperphosphorylation confers a structural predisposition to aggregate, despite the fact that in vitro at least, tau that is not phosphorylated can be induced to polymerize [151–153]. Studies of dephosphorylated, brain-derived tau suggest the phosphorylation state of tau is critical for fibril formation [129] and in fact, recombinant human tau readily aggregates when hyperphosphorylated (above 10 mol phosphate/mol protein) in vitro [20, 154]. Further, analysis of 27 different phosphomimetic mutants of recombinant tau found that phosphorylation sites nearer to the N-terminus tend to suppress tau aggregation, whereas phosphorylation sites nearer to the C-terminus, including those sites located around domains of tau which are purported to have local β -sheet competent structure, have a stimulatory effect on in vitro filament formation [155]. These data suggest that hyperphosphorylation may lead to aggregation by neutralizing inherent anti-polymerizing structural properties of tau. Hyperphosphorylation changes to the local environment and spatial arrangement of the acidic and basic regions of tau may impact tau self-polymerization, and it has been demonstrated that hyperphosphorylation may neutralize the basic charges and inherent anti-aggregation properties of tau within the acidic N-terminal inserts, allowing for tau filament formation [129].

The development of phosphorylation specific epitopes in tau has allowed researchers to correlate paired helical filament (PHF) or tau accumulation events with the phosphorylation state of tau. In fact, tau hyperphosphorylation correlates well with AD disease severity [150]. Among the first epitopes to be phosphorylated in the initial stages of tau aggregation are the KXGS motifs contained within the MT-binding region, and Ser262 in particular. Tau phosphorylated at S262 can be found in normal adult brain [141], perhaps as a regulatory modification, as it negatively affects the tau-MT association [156]. However, pS262 tau can be found free of MTs dispersed throughout the neuron [157, 158] in amorphous, aggregated state [159], suggesting this modification is a preliminary step towards tau aggregation. Following pS262 phosphorylation, pT231 is detected in many early, pre-tangle aggregated forms of tau [159]. Like pS262 tau, pT231 has reduced affinity for MTs [160] and also can be detected in non-tauopathy brains [141], potentially providing an early phospho-indicator of aggregation-prone or aggregated tau. Following phosphorylation at these sites, tau aggregates are positive for phosphoepitopes pS199, pS202, pT205, pS208 [161] as well as pS396 and pS404 [162], and the reactivity of these epitopes in tauopathy patient brains is well described [160]. Moreover, phosphorylation at pS199, pS202, pT205 promotes tau aggregation [163, 164], indicating that the modification of these residues promotes tau aggregation. The presence of mature tau aggregates such as PHFs containing seemingly regulatory phosphorylated tau at pS262 and pT231, suggests that phosphorylation which promotes tau disassembly from the MT may play an important role in the initial stages of cellular tau aggregation.

More insight regarding tau phosphorylation and aggregation can be obtained from studies using familial FTDP-17 tau mutations. Tau proteins containing G272V, P301L, V337M are more readily phosphorylated in vitro [20] while, the mutation R406W lacks several key phosphorylation sites at residues T231, S235, S396, S400, and S404 [165]. G272V, P301L, V337M and R406W all have enhanced phosphorylation at S202 compared to WT tau [20, 21]. This enhanced pS202 signature results in a conformational change (observed in vitro in gel shift mobility assays) [21] and can facilitate tau aggregation and recruitment of the normally microtubule-associated tau [20, 21]. Together, the literature indicates that the phosphorylation state of tau is linked to its aggregation and accumulation, and these effects are enhanced in the presence of familial tau mutations.

Acetylation

Acetylated tau was first identified by Min and colleagues in patients with light to moderate tau pathology, and was suggested to be a preliminary step in the accumulation of phosphorylated tau in neurofibrillary tangles [166]. While there are ~23 lysine residues in tau that are candidates for acetylation, mass spectroscopy revealed the primary acetylated residue in tau is K280 [167]. Tau acetylated at K280 is predisposed to aggregate in vitro, and can be found in tau deposits in a number of tauopathies, including PSP and AD [167], suggesting a role for tau acetylation in aggregation. However, there are some conflicting data regarding the true role of tau acetylation, as it is also reported that AD and tau transgenic mouse brains contain tau which is hypoacetylated and hyperphosphorylated specifically at KXGS motifs in the MT-binding region [168]. Further analysis reveals the deacetylase acting on these residues is histone deacetylase 6 (HDAC6) [168]. This is of note as HDAC6 protein expression is increased in AD and tau transgenic mice [169, 170], while HDAC6 inhibition promotes tau clearance [168] and rescues behavioral deficits in a tauopathy model [171]. These findings suggest a mechanism where enhanced deacetylation of tau within KXGS motifs predisposes these residues to hyperphosphorylation.

The precise mechanisms regulating tau acetylation are complex. Acetyl-transferases p300, pCAF, and CBP (CREB binding protein) have all been reported to acetylate tau, and deacetylases SIRT1 and HDAC6 have been shown to modulate deacetylation of tau at specific residues [166, 168]. Further, HDAC6 inhibition results in decreased tau-mediated toxicity, while SIRT1 levels are reduced in AD brains and correlate with an increased number of tau aggregates [172]. Finally, there is evidence that tau itself is capable of auto-acetylation [173, 174], which may have further implications for the balance of phosphorylation and acetylation in regulating tau aggregation.

Proteolytic cleavage

Finally, proteolytic cleavage of tau may play an important role in tau aggregation. Tau can be cleaved by caspases 3 and 6 at residues D421 and D348 though caspase 3 is the more effective protease [175], and tau cleaved at D421 has been identified in AD patient brain [175–177]. Further, this D421 truncated tau is prone to aggregation at a much faster rate than full-length tau [175] and can act as a seed to initiate aggregation of full-length tau, possibly as a preliminary step in tangle formation [178, 179]. Caspase cleavage of tau does not preclude hyperphosphorylation, as both modifications are often identified in tau

accumulations in post-mortem brain [175] and D421-cleaved tau can be phosphorylated by GSK3 β in vitro [178].

In addition to caspase-mediated proteolytic cleavage of tau, tau can be cleaved by calpains, thrombin, and cathepsins [180–183]. In response to beta amyloid (A β), tau is truncated to a fragment spanning residues 45–230 by calpain 1 [180], and calpain cleavage may be a common event in several tauopathies [184]. This 45–230 tau fragment is neurotoxic, though a similarly sized fragment produced by calpain 2 is not [180, 185], and can form small aggregates in the presence of arachidonic acid that partially inhibits aggregation of full-length tau [184]. Finally, it has recently been demonstrated that tau can be cleaved by legumain/mammalian asparagine endopeptidase (AEP), a cysteine protease that cleaves the C-terminal of asparagine proteases, independently of calpain or caspase cleavage [186]. Tau is cleaved by mammalian AEP at N255 and N368, and the resulting fragments bind poorly to MTs yet aggregate readily in heparin-stimulated aggregation assays, possibly because this fragmentation leaves intact the key peptide sequences for tau aggregation (residues 275–280, 306–311) [186]. Interestingly, these AEP-cleaved tau fragments are capable of becoming hyperphosphorylated [186]. Thus, tau can be cleaved by a variety of proteases, and the fragments resulting from these proteolytic events have pro-aggregatory and pro-toxicity properties, suggesting tau cleavage is likely an important determining PTM in pathological tau accumulation.

Nitration, glycosylation, glycation and other post-translational modifications of tau

In addition to acetylation and phosphorylation, tau has been reported to be modified by glycosylation [187, 188], glycation or non-enzymatic glycosylation [189, 190], prolyl-isomerization [191], nitration [192], polyamination [193], sumoylation [194], oxidation [195], ubiquitination [196, 197]. Of these PTMs, glycosylation, nitration, sumoylation, glycation and polyamination are associated with mechanisms of tau aggregation.

Tau extracted from AD patient brain is found to be glycosylated [187, 188] and deglycosylation of this material disaggregates tau and restores MT functionality to the protein [188]. In fact, O-linked glycosylation of tau has been linked to decreased phosphorylation and aggregation [198, 199], suggesting that glycosylated tau may be important in preventing unwanted aggregation of phosphorylated tau. Glycation of tau can occur at 12 different sites on tau, 7 of which are located within the MT-binding region [189, 190]; while glycation itself does not initiate tau aggregation [200], this modification appears to promote the accumulation of aggregated tau [201].

Tau derived from AD brain is normally glycosylated but de-glycosylated brain-purified tau does still assemble into fibrils [188]. Tau nitrated at residues Y18 and Y29 have been found in tangle pathology of AD patients [202–204], suggesting a role for nitration in tau accumulation. Nitration can occur at 4 sites on tau (Fig. 1) and in vitro, nitration at Y197 and E391 promotes tau polymerization [202]. These data suggest that nitration may influence tau conformation and promote aggregation. Tau sumoylated at K340 by SUMO-1, -2 and -3 has been found in tau aggregates in mutant amyloid precursor protein (APP) transgenic mice but not in transgenic tau mice, suggesting amyloid pathology is key to sumoylation of tau [194, 205]. Sumoylation therefore may represent an amyloid-driven PTM

of tau that can occur at some stage during tau accumulation, and may promote the accumulation of tau in tangles. Polyamination results in an isopeptide bond and facilitates protein cross-linking [206], and polyaminated tau has been observed in P301L mice as well as in AD brains [207, 208]. Polyaminated tau may represent a tau isoform that is cross-linked in a way that facilitates aggregation, as this modification can be detected on tau prior to accumulation [193]. Together, these PTMs represent modifications of tau which may impart the structural predisposition to aggregation. As there is a host of evidence suggesting that multiple PTMs can occur on tau simultaneously, it may be that a delicate balance of tau modification is required for normal tau function and any slight deviation from this balance predisposes it toward aggregation and accumulation.

Molecular chaperones

Cellular proteostasis is tightly controlled by a class of proteins known as molecular chaperones. The major chaperones that control proteostasis, heat shock proteins (Hsps) 90 kDa (Hsp90) and 70 kDa (Hsp70), function to regulate nascent chain protein folding, re-fold incorrect conformers of mature proteins, and if these actions fail, target the misfolded proteins to the proteasome for degradation. Therefore, chaperone proteins are ideally situated to deal with aberrant tau conformers, and the increased aggregation of tau may be linked to inappropriate tau sorting within the chaperone system. The first link of chaperones to tau biology by Dou et al. [209] found Hsp90 and tau accumulation are inversely correlated in mice overexpressing an FTD-17 mutant: brain regions containing high levels of aggregated tau had decreased Hsp90 levels, and regions with low to absent tau aggregation expressed higher levels of Hsp90. This inversely correlative trend also proved true for Hsp70 and was further confirmed in cells by Hsp90 and Hsp70 knockdown [209].

Hsp90

Hsp90 family members are encoded by 17 genes in humans which account for the predominantly cytosolic Hsp90, mitochondrial tumor necrosis factor receptor-associated protein 1 (TRAP-1), and endoplasmic reticulum (ER) resident glucose-regulated protein 94 (Grp94), each of which has a distinct set of clients and functions [210]. Early in vitro work with purified Hsp90 revealed it binds tubulin dimers and inhibits MT polymerization [211], with more recent studies implicating Hsp90 in tau regulation and MT-tau interactions [209, 212]. The findings that Hsp90 inhibitors reduced tau levels and phosphorylation through induction of the heat shock response [212, 213] or CHIP-mediated ubiquitination [214] further confirmed a role for Hsp90 in tau biology. These studies and others [215] suggest Hsp90 promotes tau re-folding, leading to the facilitation and maintenance of aberrant tau. In fact, Hsp90 was demonstrated to directly interact with tau, which promoted a conformational change in tau and enhanced its propensity to aggregate [216]. Important structural modeling work revealed that Hsp90 binds to a long stretch of tau which includes the aggregation-prone MT-binding repeat domains [217], providing mechanistic insight into how Hsp90 may facilitate tau accumulation.

The importance of co-chaperones in cellular function has been gaining increasing attention. Hsp90 co-chaperones such as FK506-binding protein 51 (FKBP51), FKBP52, cell division cycle protein 37 (Cdc37), and protein phosphatase 5 (PP5) have been shown to regulate tau

stability, aggregation, and clearance. FKBP51 and FKBP52 are immunophilins with both a tetratricopeptide repeat (TPR) and peptidyl-prolyl isomerase (PPIase) domain, permitting them to interact with tau in concert with Hsp90 or alone through cis–trans isomerization of proline residues [218]. This latter action of FKBP51 stabilizes the tau-MT interaction by altering the phosphorylation pattern of tau, an effect that can occur independently of Hsp90 [218]. However, FKBP51 and Hsp90 together have a synergistic effect on tau, preventing its clearance through the proteasome and promoting its aggregation [219]. FKBP52 also binds directly to tau, especially phosphorylated tau, inhibiting MT polymerization and tau aggregation [220]. Cdc37, which has been linked to kinase regulation, stabilizes tau and prevents its clearance through both Hsp90 and the regulation of important tau kinases [221]. Not surprisingly, the phosphatase PP5 dephosphorylates tau at several disease-relevant sites and its activity is decreased in AD brains [222, 223]. Although little data exist about how Hsp90 and PP5 regulate tau together, given the known role of each in tau biology, it is likely that they work in concert to control tau phosphorylation and proteostasis.

Hsp70

The other major cellular chaperone family is the Hsp70 family. There are over 10 members of the Hsp70 family, some with very specific subcellular locations and functions [224]. Hsp70 family proteins have been shown to bind to the MT-binding region of tau [209, 225–227]. These binding sites overlap with regions of tau important for aggregation [226] and tau binds to Hsc70 directly after MT disassembly [228], suggesting Hsc70 plays an important role in correctly directing tau after it initially disengages from the MT, which may provide insight into how Hsp70s can modulate tau aggregation. Hsp70s have a host of cofactors including DnaJ/Hsp40 family proteins, nucleotide exchange factors such as BAG proteins, and the E3 ubiquitin ligase CHIP [224]; several of these cofactors have demonstrated interactions with tau and in some cases modulate its aggregation [225, 229–232]. CHIP, responsible for ubiquitination of Hsp70 clients, is capable of binding to and ubiquitinating phosphorylated tau [225, 229] and has been shown to co-localize with pathological accumulated tau in AD, Pick's disease, PSP, and CBD [229], suggesting tau which is ubiquitinated by CHIP can be recruited into the deposits of abnormally aggregated tau. In fact, overexpression of CHIP in cells increased tau aggregation, whereas overexpression of Hsp70 reduced tau aggregation [229, 233].

Hsp70 preferentially interacts with oligomeric species of tau aggregates [233, 234]. Hsp70 can rescue tau aggregation-induced deficits in axonal transport [235], highlighting the importance of the molecular chaperone machinery in clearing tau aggregation to restore function. Due to the number of Hsp70 isoforms, it is important to delineate how each Hsp70 isoform treats tau. While tau can bind to both the constitutively expressed Hsc70 and the stress-inducible Hsp72 [226], these isoforms have opposite effects on tau: Hsp72 facilitates tau clearance, while Hsc70 stabilizes tau levels [226]. Interestingly, AD patients have greatly increased Hsc70 levels compared to Hsp72 [226]. Perhaps most strikingly, small molecule inhibitors of Hsp70 facilitate tau clearance from cells and in tau transgenic models [236, 237], and rescue deficits in synaptic plasticity [237], suggesting Hsc70-mediated stabilization of tau levels can create an environment conducive to the accumulation of tau aggregates.

Small heat shock proteins

In addition to the major cellular chaperones, other Hsps are also implicated in tau aggregation. Small Hsps such as Hsp27 (also known as HspB1) and α B crystallin (α BC/Hsp25 in rats) protect cells against stress-induced protein accumulation by interacting with misfolded proteins and preventing protein aggregation, a function dependent on the phosphorylation state of these Hsps. Small Hsps are found in both the intracellular and extracellular space [238]. The involvement of small Hsps in tauopathy is of interest, particularly since Hsp27 can bind directly to phosphorylated tau [239, 240] and Hsp27 transgenic mice have increased levels of phosphorylated tau along with the kinase, GSK3 β [241]. Hsp27 is expressed in neurons bearing tau tangles in brain regions commonly affected by AD pathology [242–244] and both Hsp27 and α BC are found co-localized with hyperphosphorylated tau in glial and astrocytic cells in several tauopathies [245–247].

In terms of tau aggregation, tau fibril formation in vitro is prevented by the addition of recombinant Hsp27, while in vivo Hsp27 overexpression results in decreased tau levels and strikingly, rescue of synaptic plasticity in a transgenic tau model [240]. In fact, Hsp27 does not dis-aggregate preformed tau aggregates, but acts specifically to inhibit fibril formation [240]. This activity was dependent on the large multimeric conformation of the Hsp27, as a phosphomimetic mutant of Hsp27 less robustly prevented tau aggregation. This mutant form of Hsp27 stabilized tau levels in mouse neurons, while wild-type Hsp27 facilitated tau clearance, suggesting that the phosphorylation dynamics of Hsp27 are critical for tau aggregation kinetics in vivo [240]. These data therefore indicate that ATP-independent small Hsps play a role in modulating tau aggregation. A recent proteomics study has indicated Hsp27 and α BC are differentially phosphorylated in brains (all cell types represented) of patients with AD compared to control brains [248]. Together, these data suggest differences in signaling pathways regulating kinases and the small Hsps in neurodegenerative disease may contribute to modulation of aggregating tau in tauopathies.

Conclusion: implications for designing effective therapies targeting cellular modulators of tau aggregation

In conclusion, tau aggregation can be affected not only by mutations associated with disease but also by a number of modifications. Direct modifications to the tau protein that alter its aggregation include tau phosphorylation, cleavage, glycosylation, nitrosylation and acetylation. Indirect modifications by binding partners such as chaperones can also have diverse effects on tau aggregation. Therefore, there are multiple mechanisms that control tau aggregation in the brain, each of which could be exploited for therapeutic development. But it remains to be seen if inhibiting tau aggregation will be effective in the clinic for AD and other tauopathies. In fact, given the diverse mechanisms through which tau aggregation can be controlled in the cell, it is possible that some types of tau aggregation could be protective while others are toxic. Thus, new investigational compounds targeting these distinct tau aggregation mechanisms could provide important insights about the pathogenesis of tau.

Acknowledgments

This work was supported by NS073899 to C.A.D.

References

1. Grundke-Iqbal I, Iqbal K, Quinlan M, Tung YC, Zaidi MS, Wisniewski HM. Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. *J Biol Chem.* 1986; 261(13):6084–6089. [PubMed: 3084478]
2. Goedert M. Tau gene mutations and their effects. *Mov Disord Off J Mov Disord Soc.* 2005; 20(Suppl 12):S45–S52.10.1002/mds.20539
3. Powers JM, Byrne NP, Ito M, Takao M, Yankopoulou D, Spillantini MG, Ghetti B. A novel leukoencephalopathy associated with tau deposits primarily in white matter glia. *Acta Neuropathol.* 2003; 106(2):181–187.10.1007/s00401-003-0719-9 [PubMed: 12783250]
4. Spillantini MG, Goedert M, Crowther RA, Murrell JR, Farlow MR, Ghetti B. Familial multiple system tauopathy with presenile dementia: a disease with abundant neuronal and glial tau filaments. *Proc Natl Acad Sci USA.* 1997; 94(8):4113–4118. [PubMed: 9108114]
5. Bird TD, Nochlin D, Poorkaj P, Cherrier M, Kaye J, Payami H, Peskind E, Lampe TH, Nemens E, Boyer PJ, Schellenberg GD. A clinical pathological comparison of three families with frontotemporal dementia and identical mutations in the tau gene (P301L). *Brain J Neurol.* 1999; 122(Pt 4):741–756.
6. Dickson DW, Ahmed Z, Algom AA, Tsuboi Y, Josephs KA. Neuropathology of variants of progressive supranuclear palsy. *Curr Opin Neurol.* 2010; 23(4):394–400.10.1097/WCO.0b013e32833be924 [PubMed: 20610990]
7. Dickson DW, Kouri N, Murray ME, Josephs KA. Neuropathology of frontotemporal lobar degeneration-tau (FTLD-tau). *J Molecul Neurosci MN.* 2011; 45(3):384–389.10.1007/s12031-011-9589-0
8. Togo T, Dickson DW. Tau accumulation in astrocytes in progressive supranuclear palsy is a degenerative rather than a reactive process. *Acta Neuropathol.* 2002; 104(4):398–402.10.1007/s00401-002-0569-x [PubMed: 12200627]
9. Iwasaki Y, Yoshida M, Hattori M, Goto A, Aiba I, Hashizume Y, Sobue G. Distribution of tuft-shaped astrocytes in the cerebral cortex in progressive supranuclear palsy. *Acta Neuropathol.* 2004; 108(5):399–405.10.1007/s00401-004-0904-5 [PubMed: 15365723]
10. Munoz DG, Ferrer I. Neuropathology of hereditary forms of frontotemporal dementia and parkinsonism. *Handbook Clin Neurol.* 2008; 89:393–414.10.1016/S0072-9752(07)01237-7
11. Takeda T, Sato T, Ito T, Sumi Y, Kobayashi T, Kitagawa M, Hirokawa K, Uchihara T. Four-repeat tau-selective deposition in subthalamic nucleus and motor cortex in Alzheimer disease. *Clin Neurol Neurosurg.* 2013; 115(5):641–643.10.1016/j.clineuro.2012.06.030 [PubMed: 22795768]
12. Neve RL, Harris P, Kosik KS, Kurnit DM, Donlon TA. Identification of cDNA clones for the human microtubule-associated protein tau and chromosomal localization of the genes for tau and microtubule-associated protein 2. *Brain Res.* 1986; 387(3):271–280. [PubMed: 3103857]
13. Majounie E, Cross W, Newsway V, Dillman A, Vandrovcova J, Morris CM, Nalls MA, Ferrucci L, Owen MJ, O'Donovan MC, Cookson, Singleton AB, de Silva R, Morris HR. Variation in tau isoform expression in different brain regions and disease states. *Neurobiol Aging.* 2013; 34(7): 1922e1912–1922e1927.10.1016/j.neurobiolaging.2013.01.017 [PubMed: 23428180]
14. Andreadis A, Brown WM, Kosik KS. Structure and novel exons of the human tau gene. *Biochemistry.* 1992; 31(43):10626–10633. [PubMed: 1420178]
15. Goedert M, Spillantini MG, Cairns NJ, Crowther RA. Tau proteins of Alzheimer paired helical filaments: abnormal phosphorylation of all six brain isoforms. *Neuron.* 1992; 8(1):159–168. [PubMed: 1530909]
16. Barghorn S, Mandelkow E. Toward a unified scheme for the aggregation of tau into Alzheimer paired helical filaments. *Biochemistry.* 2002; 41(50):14885–14896. [PubMed: 12475237]
17. Yoshida H, Crowther RA, Goedert M. Functional effects of tau gene mutations deltaN296 and N296H. *J Neurochem.* 2002; 80(3):548–551. [PubMed: 11906000]
18. Chang E, Kim S, Yin H, Nagaraja HN, Kuret J. Pathogenic missense MAPT mutations differentially modulate tau aggregation propensity at nucleation and extension steps. *J Neurochem.* 2008; 107(4):1113–1123.10.1111/j.1471-4159.2008.05692.x [PubMed: 18803694]

19. Poorkaj P, Muma NA, Zhukareva V, Cochran EJ, Shannon KM, Hurtig H, Koller WC, Bird TD, Trojanowski JQ, Lee VM, Schellenberg GD. An R5L tau mutation in a subject with a progressive supranuclear palsy phenotype. *Ann Neurol*. 2002; 52(4):511–516.10.1002/ana.10340 [PubMed: 12325083]
20. del Alonso AC, Mederlyova A, Novak M, Grundke-Iqbal I, Iqbal K. Promotion of hyperphosphorylation by frontotemporal dementia tau mutations. *J Biol Chem*. 2004; 279(33): 34873–34881.10.1074/jbc.M405131200 [PubMed: 15190058]
21. Han D, Qureshi HY, Lu Y, Paudel HK. Familial FTDP-17 missense mutations inhibit microtubule assembly-promoting activity of tau by increasing phosphorylation at Ser202 in vitro. *J Biol Chem*. 2009; 284(20):13422–13433.10.1074/jbc.M901095200 [PubMed: 19304664]
22. Conrad C, Andreadis A, Trojanowski JQ, Dickson DW, Kang D, Chen X, Wiederholt W, Hansen L, Masliah E, Thal LJ, Katzman R, Xia Y, Saitoh T. Genetic evidence for the involvement of tau in progressive supranuclear palsy. *Ann Neurol*. 1997; 41(2):277–281.10.1002/ana.410410222 [PubMed: 9029080]
23. Bikkavilli RK, Avasarala S, Van Scoyk M, Karuppusamy Rathinam MK, Tauler J, Borowicz S, Winn RA. In vitro methylation assay to study protein arginine methylation. *J Visualized Exp JoVE*. 2014; (92)10.3791/51997
24. Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S, Houlden H, Pickering-Brown S, Chakraverty S, Isaacs A, Grover A, Hackett J, Adamson J, Lincoln S, Dickson D, Davies P, Petersen RC, Stevens M, de Graaff E, Wauters E, van Baren J, Hillebrand M, Joosse M, Kwon JM, Nowotny P, Che LK, Norton J, Morris JC, Reed LA, Trojanowski J, Basun H, Lannfelt L, Neystat M, Fahn S, Dark F, Tannenberg T, Dodd PR, Hayward N, Kwok JB, Schofield PR, Andreadis A, Snowden J, Craufurd D, Neary D, Owen F, Oostra BA, Hardy J, Goate A, van Swieten J, Mann D, Lynch T, Heutink P. Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. *Nature*. 1998; 393(6686):702–705.10.1038/31508 [PubMed: 9641683]
25. Rizzu P, Van Swieten JC, Joosse M, Hasegawa M, Stevens M, Tibben A, Niermeijer MF, Hillebrand M, Ravid R, Oostra BA, Goedert M, van Duijn CM, Heutink P. High prevalence of mutations in the microtubule-associated protein tau in a population study of frontotemporal dementia in the Netherlands. *Am J Hum Genet*. 1999; 64(2):414–421.10.1086/302256 [PubMed: 9973279]
26. van Swieten JC, Stevens M, Rosso SM, Rizzu P, Joosse M, de Koning I, Kamphorst W, Ravid R, Spillantini MG, Niermeijer, Heutink P. Phenotypic variation in hereditary frontotemporal dementia with tau mutations. *Ann Neurol*. 1999; 46(4):617–626. [PubMed: 10514099]
27. Vogelsberg-Ragaglia V, Bruce J, Richter-Landsberg C, Zhang B, Hong M, Trojanowski JQ, Lee VM. Distinct FTDP-17 missense mutations in tau produce tau aggregates and other pathological phenotypes in transfected CHO cells. *Mol Biol Cell*. 2000; 11(12):4093–4104. [PubMed: 11102510]
28. Miyasaka T, Morishima-Kawashima M, Ravid R, Heutink P, van Swieten JC, Nagashima K, Ihara Y. Molecular analysis of mutant and wild-type tau deposited in the brain affected by the FTDP-17 R406W mutation. *Am J Pathol*. 2001; 158(2):373–379.10.1016/S0002-9440(10)63979-X [PubMed: 11159174]
29. Saito Y, Geyer A, Sasaki R, Kuzuhara S, Nanba E, Miyasaka T, Suzuki K, Murayama S. Early-onset, rapidly progressive familial tauopathy with R406W mutation. *Neurology*. 2002; 58(5):811–813. [PubMed: 11889249]
30. Rosso SM, van Herpen E, Pijnenburg YA, Schoonenboom NS, Scheltens P, Heutink P, van Swieten JC. Total tau and phosphorylated tau 181 levels in the cerebrospinal fluid of patients with frontotemporal dementia due to P301L and G272V tau mutations. *Arch Neurol*. 2003; 60(9):1209–1213.10.1001/archneur.60.9.1209 [PubMed: 12975285]
31. Rademakers R, Dermaut B, Peeters K, Cruts M, Heutink P, Goate A, Van Broeckhoven C. Tau (MAPT) mutation Arg406Trp presenting clinically with Alzheimer disease does not share a common founder in Western Europe. *Hum Mutat*. 2003; 22(5):409–411.10.1002/humu.10269 [PubMed: 14517953]

32. Ostojic J, Elfgren C, Passant U, Nilsson K, Gustafson L, Lannfelt L, Froelich Fabre S. The tau R406W mutation causes progressive presenile dementia with bitemporal atrophy. *Dement Geriatr Cogn Disord*. 2004; 17(4):298–301.10.1159/000077158 [PubMed: 15178940]
33. Passant U, Ostojic J, Froelich Fabre S, Gustafson L, Lannfelt L, Larsson EM, Nilsson K, Rosen I, Elfgren C. Familial presenile dementia with bitemporal atrophy. *Dement Geriatr Cogn Disord*. 2004; 17(4):287–292.10.1159/000077156 [PubMed: 15178938]
34. Lindquist SG, Holm IE, Schwartz M, Law I, Stokholm J, Batbayli M, Waldemar G, Nielsen JE. Alzheimer disease-like clinical phenotype in a family with FTDP-17 caused by a MAPT R406 W mutation. *Euro J Neurol Off J Euro Fed Neurol Soc*. 2008; 15(4):377–385.10.1111/j.1468-1331.2008.02069.x
35. Ikeuchi T, Kaneko H, Miyashita A, Nozaki H, Kasuga K, Tsukie T, Tsuchiya M, Imamura T, Ishizu H, Aoki K, Ishikawa A, Onodera O, Kuwano R, Nishizawa M. Mutational analysis in early-onset familial dementia in the Japanese population. The role of PSEN1 and MAPT R406W mutations. *Dement Geriatr Cogn Disord*. 2008; 26(1):43–49.10.1159/000141483 [PubMed: 18587238]
36. Lindquist SG, Schwartz M, Batbayli M, Waldemar G, Nielsen JE. Genetic testing in familial AD and FTD: mutation and phenotype spectrum in a Danish cohort. *Clin Genet*. 2009; 76(2):205–209.10.1111/j.1399-0004.2009.01191.x [PubMed: 19659892]
37. Dumanchin C, Camuzat A, Campion D, Verpillat P, Hannequin D, Dubois B, Saugier-Verber P, Martin C, Penet C, Charbonnier F, Agid Y, Frebourg T, Brice A. Segregation of a missense mutation in the microtubule-associated protein tau gene with familial frontotemporal dementia and parkinsonism. *Hum Mol Genet*. 1998; 7(11):1825–1829. [PubMed: 9736786]
38. Clark LN, Poorkaj P, Wszolek Z, Geschwind DH, Nasreddine ZS, Miller B, Li D, Payami H, Awert F, Markopoulou K, Andreadis A, D'Souza I, Lee VM, Reed L, Trojanowski JQ, Zhukareva V, Bird T, Schellenberg G, Wilhelmsen KC. Pathogenic implications of mutations in the tau gene in pallido-ponto-nigral degeneration and related neurodegenerative disorders linked to chromosome 17. *Proc Natl Acad Sci USA*. 1998; 95(22):13103–13107. [PubMed: 9789048]
39. Spillantini MG, Goedert M. Tau protein pathology in neurodegenerative diseases. *Trends Neurosci*. 1998; 21(10):428–433. [PubMed: 9786340]
40. Mirra SS, Murrell JR, Gearing M, Spillantini MG, Goedert M, Crowther RA, Levey AI, Jones R, Green J, Shoffner JM, Wainer BH, Schmidt ML, Trojanowski JQ, Ghetti B. Tau pathology in a family with dementia and a P301L mutation in tau. *J Neuropathol Exp Neurol*. 1999; 58(4):335–345. [PubMed: 10218629]
41. Nasreddine ZS, Loginov M, Clark LN, Lamarche J, Miller BL, Lamontagne A, Zhukareva V, Lee VM, Wilhelmsen KC, Geschwind DH. From genotype to phenotype: a clinical pathological, and biochemical investigation of frontotemporal dementia and parkinsonism (FTDP-17) caused by the P301L tau mutation. *Ann Neurol*. 1999; 45(6):704–715. [PubMed: 10360762]
42. Houlden H, Baker M, Adamson J, Grover A, Waring S, Dickson D, Lynch T, Boeve B, Petersen RC, Pickering-Brown S, Owen F, Neary D, Craufurd D, Snowden J, Mann D, Hutton M. Frequency of tau mutations in three series of non-Alzheimer's degenerative dementia. *Ann Neurol*. 1999; 46(2):243–248. [PubMed: 10443890]
43. Kodama K, Okada S, Iseki E, Kowalska A, Tabira T, Hosoi N, Yamanouchi N, Noda S, Komatsu N, Nakazato M, Kumakiri C, Yazaki M, Sato T. Familial frontotemporal dementia with a P301L tau mutation in Japan. *J Neurol Sci*. 2000; 176(1):57–64. [PubMed: 10865093]
44. Tanaka R, Kobayashi T, Motoi Y, Anno M, Mizuno Y, Mori H. A case of frontotemporal dementia with tau P301L mutation in the Far East. *J Neurol*. 2000; 247(9):705–707. [PubMed: 11081811]
45. Rizzo P, Joosse M, Ravid R, Hoogeveen A, Kamphorst W, van Swieten JC, Willemsen R, Heutink P. Mutation-dependent aggregation of tau protein and its selective depletion from the soluble fraction in brain of P301L FTDP-17 patients. *Hum Mol Genet*. 2000; 9(20):3075–3082. [PubMed: 11115852]
46. von Bergen M, Barghorn S, Li L, Marx A, Biernat J, Mandelkow EM, Mandelkow E. Mutations of tau protein in frontotemporal dementia promote aggregation of paired helical filaments by enhancing local beta-structure. *J Biol Chem*. 2001; 276(51):48165–48174.10.1074/jbc.M105196200 [PubMed: 11606569]

47. Poorkaj P, Grossman M, Steinbart E, Payami H, Sadovnick A, Nochlin D, Tabira T, Trojanowski JQ, Borson S, Galasko D, Reich S, Quinn B, Schellenberg G, Bird TD. Frequency of tau gene mutations in familial and sporadic cases of non-Alzheimer dementia. *Arch Neurol*. 2001; 58(3): 383–387. [PubMed: 11255441]
48. Kowalska A, Asada T, Arima K, Kumakiri C, Kozubski W, Takahashi K, Tabira T. Genetic analysis in patients with familial and sporadic frontotemporal dementia: two tau mutations in only familial cases and no association with apolipoprotein epsilon4. *Dement Geriatr Cogn Disord*. 2001; 12(6):387–392. (51285). [PubMed: 11598310]
49. Kobayashi T, Mori H, Okuma Y, Dickson DW, Cookson N, Tsuboi Y, Motoi Y, Tanaka R, Miyashita N, Anno M, Narabayashi H, Mizuno Y. Contrasting genotypes of the tau gene in two phenotypically distinct patients with P301L mutation of frontotemporal dementia and parkinsonism linked to chromosome 17. *J Neurol*. 2002; 249(6):669–675.10.1007/s00415-002-0687-3 [PubMed: 12111297]
50. Walker RH, Friedman J, Wiener J, Hobler R, Gwinn-Hardy K, Adam A, DeWolfe J, Gibbs R, Baker M, Farrer M, Hutton M, Hardy J. A family with a tau P301L mutation presenting with parkinsonism. *Parkinsonism Related Disorders*. 2002; 9(2):121–123. [PubMed: 12473404]
51. Binetti G, Nicosia F, Benussi L, Ghidoni R, Feudatari E, Barbiero L, Signorini S, Villa A, Mattioli F, Zanetti O, Alberici A. Prevalence of TAU mutations in an Italian clinical series of familial frontotemporal patients. *Neurosci Lett*. 2003; 338(1):85–87. [PubMed: 12565146]
52. Sobrido MJ, Miller BL, Havlioglu N, Zhukareva V, Jiang Z, Nasreddine ZS, Lee VM, Chow TW, Wilhelmsen KC, Cummings JL, Wu JY, Geschwind DH. Novel tau polymorphisms, tau haplotypes, and splicing in familial and sporadic frontotemporal dementia. *Arch Neurol*. 2003; 60(5):698–702.10.1001/archneur.60.5.698 [PubMed: 12756133]
53. Stanford PM, Brooks WS, Teber ET, Hallupp M, McLean C, Halliday GM, Martins RN, Kwok JB, Schofield PR. Frequency of tau mutations in familial and sporadic frontotemporal dementia and other tauopathies. *J Neurol*. 2004; 251(9):1098–1104.10.1007/s00415-004-0489-x [PubMed: 15372253]
54. Benussi L, Ghidoni R, Paterlini A, Nicosia F, Alberici AC, Signorini S, Barbiero L, Binetti G. Interaction between tau and alpha-synuclein proteins is impaired in the presence of P301L tau mutation. *Exp Cell Res*. 2005; 308(1):78–84.10.1016/j.yexcr.2005.04.021 [PubMed: 15904919]
55. Llado A, Sanchez-Valle R, Rey MJ, Ezquerro M, Tolosa E, Ferrer I, Molinuevo JL. Catalan collaborative Study Group for F. Clinicopathological and genetic correlates of frontotemporal lobar degeneration and corticobasal degeneration. *J Neurol*. 2008; 255(4):488–494.10.1007/s00415-008-0565-8 [PubMed: 18357425]
56. Lopez de Munain A, Alzualde A, Gorostidi A, Otaegui D, Ruiz-Martinez J, Indakoetxea B, Ferrer I, Perez-Tur J, Saenz A, Bergareche A, Barandiaran M, Poza JJ, Zabalza R, Ruiz I, Urtasun M, Fernandez-Manchola I, Olasagasti B, Espinal JB, Olaskoaga J, Ruibal M, Moreno F, Carrera N, Marti Masso JF. Mutations in progranulin gene: clinical, pathological, and ribonucleic acid expression findings. *Biol Psychiatry*. 2008; 63(10):946–952.10.1016/j.biopsych.2007.08.015 [PubMed: 17950702]
57. Bugiani O, Murrell JR, Giaccone G, Hasegawa M, Ghigo G, Tabaton M, Morbin M, Primavera A, Carella F, Solaro C, Grisoli M, Savoirdo M, Spillantini MG, Tagliavini F, Goedert M, Ghetti B. Frontotemporal dementia and corticobasal degeneration in a family with a P301S mutation in tau. *J Neuropathol Exp Neurol*. 1999; 58(6):667–677. [PubMed: 10374757]
58. Sperfeld AD, Collatz MB, Baier H, Palmbach M, Storch A, Schwarz J, Tatsch K, Reske S, Joosse M, Heutink P, Ludolph AC. FTDP-17: an early-onset phenotype with parkinsonism and epileptic seizures caused by a novel mutation. *Ann Neurol*. 1999; 46(5):708–715. [PubMed: 10553987]
59. Yasuda M, Yokoyama K, Nakayasu T, Nishimura Y, Matsui M, Yokoyama T, Miyoshi K, Tanaka C. A Japanese patient with frontotemporal dementia and parkinsonism by a tau P301S mutation. *Neurology*. 2000; 55(8):1224–1227. [PubMed: 11071507]
60. Morris HR, Schrag A, Nath U, Burn D, Quinn NP, Daniel S, Wood NW, Lees AJ. Effect of ApoE and tau on age of onset of progressive supranuclear palsy and multiple system atrophy. *Neurosci Lett*. 2001; 312(2):118–120. [PubMed: 11595348]
61. Lossos A, Reches A, Gal A, Newman JP, Soffer D, Gomori JM, Boher M, Ekstein D, Biran I, Meiner Z, Abramsky O, Rosenmann H. Frontotemporal dementia and parkinsonism with the

- P301S tau gene mutation in a Jewish family. *J Neurol.* 2003; 250(6):733–740.10.1007/s00415-003-1074-4 [PubMed: 12796837]
62. Huey ED, Grafman J, Wassermann EM, Pietrini P, Tierney MC, Ghetti B, Spina S, Baker M, Hutton M, Elder JW, Berger SL, Heflin KA, Hardy J, Momeni P. Characteristics of frontotemporal dementia patients with a Progranulin mutation. *Ann Neurol.* 2006; 60(3):374–380.10.1002/ana.20969 [PubMed: 16983677]
 63. Han D, Paudel HK. FTDP-17 missense mutations site-specifically inhibit as well as promote dephosphorylation of microtubule-associated protein tau by protein phosphatases of HEK-293 cell extract. *Neurochem Int.* 2009; 54(1):14–27.10.1016/j.neuint.2008.09.014 [PubMed: 18992292]
 64. Heutink P, Stevens M, Rizzu P, Bakker E, Kros JM, Tibben A, Niermeijer MF, van Duijn CM, Oostra BA, van Swieten JC. Hereditary frontotemporal dementia is linked to chromosome 17q21-q22: a genetic and clinicopathological study of three Dutch families. *Ann Neurol.* 1997; 41(2):150–159.10.1002/ana.410410205 [PubMed: 9029063]
 65. Spillantini MG, Crowther RA, Kamphorst W, Heutink P, van Swieten JC. Tau pathology in two Dutch families with mutations in the microtubule-binding region of tau. *Am J Pathol.* 1998; 153(5):1359–1363.10.1016/S0002-9440(10)65721-5 [PubMed: 9811325]
 66. Bronner IF, ter Meulen BC, Azmani A, Severijnen LA, Willemsen R, Kamphorst W, Ravid R, Heutink P, van Swieten JC. Hereditary Pick's disease with the G272V tau mutation shows predominant three-repeat tau pathology. *Brain : a journal of neurology.* 2005; 128(Pt 11):2645–2653.10.1093/brain/awh591 [PubMed: 16014652]
 67. Neumann M, Diekmann S, Bertsch U, Vanmassenhove B, Bogerts B, Kretschmar HA. Novel G335V mutation in the tau gene associated with early onset familial frontotemporal dementia. *Neurogenetics.* 2005; 6(2):91–95.10.1007/s10048-005-0210-y [PubMed: 15765246]
 68. Arima K, Kowalska A, Hasegawa M, Mukoyama M, Watanabe R, Kawai M, Takahashi K, Iwatsubo T, Tabira T, Sunohara N. Two brothers with frontotemporal dementia and parkinsonism with an N279K mutation of the tau gene. *Neurology.* 2000; 54(9):1787–1795. [PubMed: 10802785]
 69. Rossi G, Gasparoli E, Pasquali C, Di Fede G, Testa D, Albanese A, Bracco F, Tagliavini F. Progressive supranuclear palsy and Parkinson's disease in a family with a new mutation in the tau gene. *Ann Neurol.* 2004; 55(3):448.10.1002/ana.20006 [PubMed: 14991829]
 70. Ros R, Thobois S, Streichenberger N, Kopp N, Sanchez MP, Perez M, Hoenicka J, Avila J, Honnorat J, de Yébenes JG. A new mutation of the tau gene, G303V, in early-onset familial progressive supranuclear palsy. *Arch Neurol.* 2005; 62(9):1444–1450.10.1001/archneur.62.9.1444 [PubMed: 16157753]
 71. Neumann M, Mittelbronn M, Simon P, Vanmassenhove B, de Silva R, Lees A, Klapp J, Meyermann R, Kretschmar HA. A new family with frontotemporal dementia with intronic 10+3 splice site mutation in the tau gene: neuropathology and molecular effects. *Neuropathol Appl Neurobiol.* 2005; 31(4):362–373.10.1111/j.1365-2990.2005.00629.x [PubMed: 16008820]
 72. Iseki E, Matsumura T, Marui W, Hino H, Odawara T, Sugiyama N, Suzuki K, Sawada H, Arai T, Kosaka K. Familial frontotemporal dementia and parkinsonism with a novel N296H mutation in exon 10 of the tau gene and a widespread tau accumulation in the glial cells. *Acta Neuropathol.* 2001; 102(3):285–292. [PubMed: 11585254]
 73. Grover A, England E, Baker M, Sahara N, Adamson J, Granger B, Houlden H, Passant U, Yen SH, DeTure M, Hutton M. A novel tau mutation in exon 9 (1260 V) causes a four-repeat tauopathy. *Exp Neurol.* 2003; 184(1):131–140. [PubMed: 14637086]
 74. Hogg M, Grubic ZM, Baker M, Demirci S, Guillozet AL, Sweet AP, Herzog LL, Weintraub S, Mesulam MM, LaPointe NE, Gamblin TC, Berry RW, Binder LI, de Silva R, Lees A, Espinoza M, Davies P, Grover A, Sahara N, Ishizawa T, Dickson D, Yen SH, Hutton M, Bigio EH. The L266 V tau mutation is associated with frontotemporal dementia and Pick-like 3R and 4R tauopathy. *Acta Neuropathol.* 2003; 106(4):323–336.10.1007/s00401-003-0734-x [PubMed: 12883828]
 75. Kobayashi T, Ota S, Tanaka K, Ito Y, Hasegawa M, Umeda Y, Motoi Y, Takanashi M, Yasuhara M, Anno M, Mizuno Y, Mori H. A novel L266 V mutation of the tau gene causes frontotemporal dementia with a unique tau pathology. *Ann Neurol.* 2003; 53(1):133–137.10.1002/ana.10447 [PubMed: 12509859]

76. Hayashi S, Toyoshima Y, Hasegawa M, Umeda Y, Wakabayashi K, Tokiguchi S, Iwatsubo T, Takahashi H. Late-onset frontotemporal dementia with a novel exon 1 (Arg5His) tau gene mutation. *Ann Neurol.* 2002; 51(4):525–530. [PubMed: 11921059]
77. Hutton M. “Missing” tau mutation identified. *Ann Neurol.* 2000; 47(4):417–418. [PubMed: 10762149]
78. Yasuda M, Takamatsu J, D’Souza I, Crowther RA, Kawamata T, Hasegawa M, Hasegawa H, Spillantini MG, Tanimukai S, Poorkaj P, Varani L, Varani G, Iwatsubo T, Goedert M, Schellenberg DG, Tanaka C. A novel mutation at position +12 in the intron following exon 10 of the tau gene in familial frontotemporal dementia (FTD-Kumamoto). *Ann Neurol.* 2000; 47(4): 422–429. [PubMed: 10762152]
79. Pickering-Brown SM, Richardson AM, Snowden JS, McDonagh AM, Burns A, Braude W, Baker M, Liu WK, Yen SH, Hardy J, Hutton M, Davies Y, Allsop D, Craufurd D, Neary D, Mann DM. Inherited frontotemporal dementia in nine British families associated with intronic mutations in the tau gene. *Brain J Neurol.* 2002; 125(Pt 4):732–751.
80. Barghorn S, Biernat J, Mandelkow E. Purification of recombinant tau protein and preparation of Alzheimer-paired helical filaments in vitro. *Methods Mol Biol.* 2005; 299:35–51. [PubMed: 15980594]
81. Barghorn S, Zheng-Fischhofer Q, Ackmann M, Biernat J, von Bergen M, Mandelkow EM, Mandelkow E. Structure, microtubule interactions, and paired helical filament aggregation by tau mutants of frontotemporal dementias. *Biochemistry.* 2000; 39(38):11714–11721. [PubMed: 10995239]
82. von Bergen M, Barghorn S, Jeganathan S, Mandelkow EM, Mandelkow E. Spectroscopic approaches to the conformation of tau protein in solution and in paired helical filaments. *Neuro Degener Dis.* 2006; 3(4–5):197–206.10.1159/000095257
83. von Bergen M, Friedhoff P, Biernat J, Heberle J, Mandelkow EM, Mandelkow E. Assembly of tau protein into Alzheimer paired helical filaments depends on a local sequence motif ((306)VQIVYK(311)) forming beta structure. *Proc Natl Acad Sci USA.* 2000; 97(10):5129–5134. [PubMed: 10805776]
84. von Bergen M, Li L, Mandelkow E. Intrinsic fluorescent detection of tau conformation and aggregation. *Methods Mol Biol.* 2005; 299:175–184. [PubMed: 15980601]
85. Biernat J, Gustke N, Drewes G, Mandelkow EM, Mandelkow E. Phosphorylation of Ser262 strongly reduces binding of tau to microtubules: distinction between PHF-like immunoreactivity and microtubule binding. *Neuron.* 1993; 11(1):153–163. [PubMed: 8393323]
86. Schweers O, Schonbrunn-Hanebeck E, Marx A, Mandelkow E. Structural studies of tau protein and Alzheimer paired helical filaments show no evidence for beta-structure. *J Biol Chem.* 1994; 269(39):24290–24297. [PubMed: 7929085]
87. Mylonas E, Hascher A, Bernado P, Blackledge M, Mandelkow E, Svergun DI. Domain conformation of tau protein studied by solution small-angle X-ray scattering. *Biochemistry.* 2008; 47(39):10345–10353.10.1021/bi800900d [PubMed: 18771286]
88. Jeganathan S, von Bergen M, Mandelkow EM, Mandelkow E. The natively unfolded character of tau and its aggregation to Alzheimer-like paired helical filaments. *Biochemistry.* 2008; 47(40): 10526–10539.10.1021/bi800783d [PubMed: 18783251]
89. Uversky VN. Natively unfolded proteins: a point where biology waits for physics. *Protein Sci Publ Protein Soc.* 2002; 11(4):739–756.10.1110/ps.4210102
90. Jicha GA, Bowser R, Kazam IG, Davies P. Alz-50 and MC-1, a new monoclonal antibody raised to paired helical filaments, recognize conformational epitopes on recombinant tau. *J Neurosci Res.* 1997; 48(2):128–132. [PubMed: 9130141]
91. Carmel G, Mager EM, Binder LI, Kuret J. The structural basis of monoclonal antibody Alz50’s selectivity for Alzheimer’s disease pathology. *J Biol Chem.* 1996; 271(51):32789–32795. [PubMed: 8955115]
92. Jeganathan S, von Bergen M, Brtlich H, Steinhoff HJ, Mandelkow E. Global hairpin folding of tau in solution. *Biochemistry.* 2006; 45(7):2283–2293.10.1021/bi0521543 [PubMed: 16475817]

93. Mukrasch MD, Bibow S, Korukottu J, Jeganathan S, Biernat J, Griesinger C, Mandelkow E, Zweckstetter M. Structural polymorphism of 441-residue tau at single residue resolution. *PLoS Biol.* 2009; 7(2):e34.10.1371/journal.pbio.1000034 [PubMed: 19226187]
94. Elbaum-Garfinkle S, Rhoades E. Identification of an aggregation-prone structure of tau. *J Am Chem Soc.* 2012; 134(40):16607–16613.10.1021/ja305206m [PubMed: 22998648]
95. Weingarten MD, Lockwood AH, Hwo SY, Kirschner MW. A protein factor essential for microtubule assembly. *Proc Natl Acad Sci USA.* 1975; 72(5):1858–1862. [PubMed: 1057175]
96. Goode BL, Denis PE, Panda D, Radeke MJ, Miller HP, Wilson L, Feinstein SC. Functional interactions between the proline-rich and repeat regions of tau enhance microtubule binding and assembly. *Mol Biol Cell.* 1997; 8(2):353–365. [PubMed: 9190213]
97. Breuzard G, Hubert P, Nouar R, De Bessa T, Devred F, Barbier P, Sturgis JN, Peyrot V. Molecular mechanisms of Tau binding to microtubules and its role in microtubule dynamics in live cells. *J Cell Sci.* 2013; 126(Pt 13):2810–2819.10.1242/jcs.120832 [PubMed: 23659998]
98. Bunker JM, Wilson L, Jordan MA, Feinstein SC. Modulation of microtubule dynamics by tau in living cells: implications for development and neurodegeneration. *Mol Biol Cell.* 2004; 15(6):2720–2728.10.1091/mbc.E04-01-0062 [PubMed: 15020716]
99. Choi MC, Raviv U, Miller HP, Gaylord MR, Kiris E, Ventimiglia D, Needleman DJ, Kim MW, Wilson L, Feinstein SC, Safinya CR. Human microtubule-associated-protein tau regulates the number of protofilaments in microtubules: a synchrotron x-ray scattering study. *Biophys J.* 2009; 97(2):519–527.10.1016/j.bpj.2009.04.047 [PubMed: 19619466]
100. Panda D, Samuel JC, Massie M, Feinstein SC, Wilson L. Differential regulation of microtubule dynamics by three- and four-repeat tau: implications for the onset of neurodegenerative disease. *Proc Natl Acad Sci USA.* 2003; 100(16):9548–9553.10.1073/pnas.1633508100 [PubMed: 12886013]
101. Fischer D, Mukrasch MD, von Bergen M, Klos-Witkowska A, Biernat J, Griesinger C, Mandelkow E, Zweckstetter M. Structural and microtubule binding properties of tau mutants of frontotemporal dementias. *Biochemistry.* 2007; 46(10):2574–2582.10.1021/bi061318s [PubMed: 17297915]
102. van Herpen E, Rosso SM, Serverijnen LA, Yoshida H, Breedveld G, van de Graaf R, Kamphorst W, Ravid R, Willemsen R, Dooijes D, Majoor-Krakauer D, Kros JM, Crowther RA, Goedert M, Heutink P, van Swieten JC. Variable phenotypic expression and extensive tau pathology in two families with the novel tau mutation L315R. *Ann Neurol.* 2003; 54(5):573–581.10.1002/ana.10721 [PubMed: 14595646]
103. Hasegawa M, Smith MJ, Goedert M. Tau proteins with FTDP-17 mutations have a reduced ability to promote microtubule assembly. *FEBS Lett.* 1998; 437(3):207–210. [PubMed: 9824291]
104. Hasegawa M, Smith MJ, Iijima M, Tabira T, Goedert M. FTDP-17 mutations N279 K and S305 N in tau produce increased splicing of exon 10. *FEBS Lett.* 1999; 443(2):93–96. [PubMed: 9989582]
105. Iyer A, Lapointe NE, Zielke K, Berdynski M, Guzman E, Barczak A, Chodakowska-Zebrowska M, Barcikowska M, Feinstein S, Zekanowski C. A novel MAPT mutation, G55R, in a frontotemporal dementia patient leads to altered Tau function. *PLoS ONE.* 2013; 8(9):e76409.10.1371/journal.pone.0076409 [PubMed: 24086739]
106. Pooler AM, Usardi A, Evans CJ, Philpott KL, Noble W, Hanger DP. Dynamic association of tau with neuronal membranes is regulated by phosphorylation. *Neurobiol Aging.* 2012; 33(2):431e427–431e438.10.1016/j.neurobiolaging.2011.01.005 [PubMed: 21388709]
107. Brandt R, Leger J, Lee G. Interaction of tau with the neural plasma membrane mediated by tau's amino-terminal projection domain. *J Cell Biol.* 1995; 131(5):1327–1340. [PubMed: 8522593]
108. Dixit R, Ross JL, Goldman YE, Holzbaur EL. Differential regulation of dynein and kinesin motor proteins by tau. *Science.* 2008; 319(5866):1086–1089.10.1126/science.1152993 [PubMed: 18202255]
109. Yu D, LaPointe NE, Guzman E, Pessino V, Wilson L, Feinstein SC, Valentine MT. Tau proteins harboring neurodegeneration-linked mutations impair kinesin translocation in vitro. *J Alzheimer's Dis JAD.* 2014; 39(2):301–314.10.3233/JAD-131274

110. Gilley J, Seereeram A, Ando K, Mosely S, Andrews S, Kerschensteiner M, Misgeld T, Brion JP, Anderton B, Hanger DP, Coleman MP. Age-dependent axonal transport and locomotor changes and tau hypophosphorylation in a "P301L" tau knockin mouse. *Neurobiol Aging*. 2012; 33(3): 621e615–621e621.10.1016/j.neurobiolaging.2011.02.014 [PubMed: 21492964]
111. Zhang B, Higuchi M, Yoshiyama Y, Ishihara T, Forman MS, Martinez D, Joyce S, Trojanowski JQ, Lee VM. Retarded axonal transport of R406 W mutant tau in transgenic mice with a neurodegenerative tauopathy. *J Neurosci Off J Soc Neurosci*. 2004; 24(19):4657–4667.10.1523/JNEUROSCI.0797-04.2004
112. Loomis PA, Howard TH, Castleberry RP, Binder LI. Identification of nuclear tau isoforms in human neuroblastoma cells. *Proc Natl Acad Sci USA*. 1990; 87(21):8422–8426. [PubMed: 1700432]
113. Sultan A, Nesslany F, Violet M, Begard S, Loyens A, Talahari S, Mansuroglu Z, Marzin D, Sergeant N, Humez S, Colin M, Bonnefoy E, Buee L, Galas MC. Nuclear tau, a key player in neuronal DNA protection. *J Biol Chem*. 2011; 286(6):4566–4575.10.1074/jbc.M110.199976 [PubMed: 21131359]
114. Sjoberg MK, Shestakova E, Mansuroglu Z, Maccioni RB, Bonnefoy E. Tau protein binds to pericentromeric DNA: a putative role for nuclear tau in nucleolar organization. *J Cell Sci*. 2006; 119(Pt 10):2025–2034.10.1242/jcs.02907 [PubMed: 16638814]
115. Sugino E, Nishiura C, Minoura K, In Y, Sumida M, Taniguchi T, Tomoo K, Ishida T. Three-/four-repeat-dependent aggregation profile of tau microtubule-binding domain clarified by dynamic light scattering analysis. *Biochem Biophys Res Commun*. 2009; 385(2):236–240.10.1016/j.bbrc.2009.05.047 [PubMed: 19450558]
116. von Bergen M, Barghorn S, Muller SA, Pickhardt M, Biernat J, Mandelkow EM, Davies P, Aebl U, Mandelkow E. The core of tau-paired helical filaments studied by scanning transmission electron microscopy and limited proteolysis. *Biochemistry*. 2006; 45(20):6446–6457.10.1021/bi052530j [PubMed: 16700555]
117. Necula M, Kuret J. A static laser light scattering assay for surfactant-induced tau fibrillization. *Anal Biochem*. 2004; 333(2):205–215.10.1016/j.ab.2004.05.044 [PubMed: 15450794]
118. Necula M, Kuret J. Electron microscopy as a quantitative method for investigating tau fibrillization. *Anal Biochem*. 2004; 329(2):238–246.10.1016/j.ab.2004.02.023 [PubMed: 15158482]
119. Lippens G, Sillen A, Smet C, Wieruszeski JM, Leroy A, Buee L, Landrieu I. Studying the natively unfolded neuronal Tau protein by solution NMR spectroscopy. *Protein Pept Lett*. 2006; 13(3):235–246. [PubMed: 16515451]
120. Akoury E, Pickhardt M, Gajda M, Biernat J, Mandelkow E, Zweckstetter M. Mechanistic basis of phenothiazine-driven inhibition of Tau aggregation. *Angew Chem*. 2013; 52(12):3511–3515.10.1002/anie.201208290 [PubMed: 23401175]
121. Daebel V, Chinnathambi S, Biernat J, Schwalbe M, Habenstein B, Loquet A, Akoury E, Tepper K, Muller H, Baldus M, Griesinger C, Zweckstetter M, Mandelkow E, Vijayan V, Lange A. beta-Sheet core of tau paired helical filaments revealed by solid-state NMR. *J Am Chem Soc*. 2012; 134(34):13982–13989.10.1021/ja305470p [PubMed: 22862303]
122. Ramachandran G, Udgaonkar JB. Mechanistic studies unravel the complexity inherent in tau aggregation leading to Alzheimer's disease and the tauopathies. *Biochemistry*. 2013; 52(24): 4107–4126.10.1021/bi400209z [PubMed: 23721410]
123. Perez M, Valpuesta JM, Medina M, Montejo de Garcini E, Avila J. Polymerization of tau into filaments in the presence of heparin: the minimal sequence required for tau-tau interaction. *J Neurochem*. 1996; 67(3):1183–1190. [PubMed: 8752125]
124. Goedert M, Jakes R, Spillantini MG, Hasegawa M, Smith MJ, Crowther RA. Assembly of microtubule-associated protein tau into Alzheimer-like filaments induced by sulphated glycosaminoglycans. *Nature*. 1996; 383(6600):550–553.10.1038/383550a0 [PubMed: 8849730]
125. Kampers T, Friedhoff P, Biernat J, Mandelkow EM, Mandelkow E. RNA stimulates aggregation of microtubule-associated protein tau into Alzheimer-like paired helical filaments. *FEBS Lett*. 1996; 399(3):344–349. [PubMed: 8985176]

126. Kampers T, Pangalos M, Geerts H, Wiech H, Mandelkow E. Assembly of paired helical filaments from mouse tau: implications for the neurofibrillary pathology in transgenic mouse models for Alzheimer's disease. *FEBS Lett.* 1999; 451(1):39–44. [PubMed: 10356980]
127. Gamblin TC, King ME, Dawson H, Vitek MP, Kuret J, Berry RW, Binder LI. In vitro polymerization of tau protein monitored by laser light scattering: method and application to the study of FTDP-17 mutants. *Biochemistry.* 2000; 39(20):6136–6144. [PubMed: 10821687]
128. King ME, Ahuja V, Binder LI, Kuret J. Ligand-dependent tau filament formation: implications for Alzheimer's disease progression. *Biochemistry.* 1999; 38(45):14851–14859. [PubMed: 10555967]
129. Alonso A, Zaidi T, Novak M, Grundke-Iqbal I, Iqbal K. Hyperphosphorylation induces self-assembly of tau into tangles of paired helical filaments/straight filaments. *Proc Natl Acad Sci USA.* 2001; 98(12):6923–6928.10.1073/pnas.121119298 [PubMed: 11381127]
130. Wang JZ, Grundke-Iqbal I, Iqbal K. Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration. *Euro J Neurosci.* 2007; 25(1):59–68.10.1111/j.1460-9568.2006.05226.x
131. Nath A, Sammakorpi M, DeWitt DC, Trexler AJ, Elbaum-Garfinkle S, O'Hern CS, Rhoades E. The conformational ensembles of alpha-synuclein and tau: combining single-molecule FRET and simulations. *Biophys J.* 2012; 103(9):1940–1949.10.1016/j.bpj.2012.09.032 [PubMed: 23199922]
132. Eliezer D, Barre P, Kobaslija M, Chan D, Li X, Heend L. Residual structure in the repeat domain of tau: echoes of microtubule binding and paired helical filament formation. *Biochemistry.* 2005; 44(3):1026–1036.10.1021/bi048953n [PubMed: 15654759]
133. Yu X, Luo Y, Dinkel P, Zheng J, Wei G, Margittai M, Nussinov R, Ma B. Cross-seeding and conformational selection between three- and four-repeat human Tau proteins. *J Biol Chem.* 2012; 287(18):14950–14959.10.1074/jbc.M112.340794 [PubMed: 22393063]
134. Luo Y, Ma B, Nussinov R, Wei G. Structural insight into tau protein's paradox of intrinsically disordered behavior, self-acetylation activity, and aggregation. *J Phys Chem Lett.* 2014; 5(17):3026–3031.10.1021/jz501457f [PubMed: 25206938]
135. Perez M, Arrasate M, Montejo De Garcini E, Munoz V, Avila J. In vitro assembly of tau protein: mapping the regions involved in filament formation. *Biochemistry.* 2001; 40(20):5983–5991. [PubMed: 11352733]
136. Abraha A, Ghoshal N, Gamblin TC, Cryns V, Berry RW, Kuret J, Binder LI. C-terminal inhibition of tau assembly in vitro and in Alzheimer's disease. *J Cell Sci.* 2000; 113(Pt 21):3737–3745. [PubMed: 11034902]
137. Sergeant N, Bretteville A, Hamdane M, Caillet-Boudin ML, Grognet P, Bombois S, Blum D, Delacourte A, Pasquier F, Vanmechelen E, Schraen-Maschke S, Buee L. Biochemistry of Tau in Alzheimer's disease and related neurological disorders. *Expert Rev Proteomic.* 2008; 5(2):207–224.10.1586/14789450.5.2.207
138. Bramblett GT, Goedert M, Jakes R, Merrick SE, Trojanowski JQ, Lee VM. Abnormal tau phosphorylation at Ser396 in Alzheimer's disease recapitulates development and contributes to reduced microtubule binding. *Neuron.* 1993; 10(6):1089–1099. [PubMed: 8318230]
139. Yoshida H, Ihara Y. Tau in paired helical filaments is functionally distinct from fetal tau: assembly incompetence of paired helical filament-tau. *J Neurochem.* 1993; 61(3):1183–1186. [PubMed: 8360683]
140. Poppek D, Keck S, Ermak G, Jung T, Stolzinger A, Ullrich O, Davies KJ, Grune T. Phosphorylation inhibits turnover of the tau protein by the proteasome: influence of RCAN1 and oxidative stress. *Biochem J.* 2006; 400(3):511–520.10.1042/BJ20060463 [PubMed: 16939415]
141. Watanabe A, Hasegawa M, Suzuki M, Takio K, Morishima-Kawashima M, Titani K, Arai T, Kosik KS, Ihara Y. In vivo phosphorylation sites in fetal and adult rat tau. *J Biol Chem.* 1993; 268(34):25712–25717. [PubMed: 8245007]
142. Liu MC, Kobeissy F, Zheng W, Zhang Z, Hayes RL, Wang KK. Dual vulnerability of tau to calpains and caspase-3 proteolysis under neurotoxic and neurodegenerative conditions. *ASN Neuro.* 2011; 3(1):e00051.10.1042/AN20100012 [PubMed: 21359008]

143. Takahashi RH, Capetillo-Zarate E, Lin MT, Milner TA, Gouras GK. Co-occurrence of Alzheimer's disease ss-amyloid and tau pathologies at synapses. *Neurobiol Aging*. 2010; 31(7): 1145–1152.10.1016/j.neurobiolaging.2008.07.021 [PubMed: 18771816]
144. Hanger DP, Hughes K, Woodgett JR, Brion JP, Anderton BH. Glycogen synthase kinase-3 induces Alzheimer's disease-like phosphorylation of tau: generation of paired helical filament epitopes and neuronal localisation of the kinase. *Neurosci Lett*. 1992; 147(1):58–62. [PubMed: 1336152]
145. Vega IE, Cui L, Propst JA, Hutton ML, Lee G, Yen SH. Increase in tau tyrosine phosphorylation correlates with the formation of tau aggregates. *Brain Res Mol Brain Res*. 2005; 138(2):135–144.10.1016/j.molbrainres.2005.04.015 [PubMed: 15913839]
146. Dolan PJ, Johnson GV. The role of tau kinases in Alzheimer's disease. *Curr Opin Drug Discov Devel*. 2010; 13(5):595–603.
147. Lee VM, Brunden KR, Hutton M, Trojanowski JQ. Developing therapeutic approaches to tau, selected kinases, and related neuronal protein targets. *Cold Spring Harbor Perspect Med*. 2011; 1(1):a006437.10.1101/cshperspect.a006437
148. Martin L, Latypova X, Wilson CM, Magnaudeix A, Perrin ML, Yardin C, Terro F. Tau protein kinases: involvement in Alzheimer's disease. *Ageing Res Rev*. 2013; 12(1):289–309.10.1016/j.arr.2012.06.003 [PubMed: 22742992]
149. Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. *Proc Natl Acad Sci USA*. 1986; 83(13):4913–4917. [PubMed: 3088567]
150. Augustinack JC, Schneider A, Mandelkow EM, Hyman BT. Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. *Acta Neuropathol*. 2002; 103(1):26–35. [PubMed: 11837744]
151. Crowther RA, Olesen OF, Smith MJ, Jakes R, Goedert M. Assembly of Alzheimer-like filaments from full-length tau protein. *FEBS Lett*. 1994; 337(2):135–138. [PubMed: 8287967]
152. Montejo de Garcini E, Serrano L, Avila J. Self assembly of microtubule associated protein tau into filaments resembling those found in Alzheimer disease. *Biochem Biophys Res Commun*. 1986; 141(2):790–796. [PubMed: 3099793]
153. Wille H, Drewes G, Biernat J, Mandelkow EM, Mandelkow E. Alzheimer-like paired helical filaments and antiparallel dimers formed from microtubule-associated protein tau in vitro. *J Cell Biol*. 1992; 118(3):573–584. [PubMed: 1639844]
154. Dolai S, Shi W, Corbo C, Sun C, Averick S, Obeysekera D, Farid M, Alonso A, Banerjee P, Raja K. "Clicked" sugar-curcumin conjugate: modulator of amyloid-beta and tau peptide aggregation at ultralow concentrations. *ACS Chem Neurosci*. 2011; 2(12):694–699.10.1021/cn200088r [PubMed: 22860163]
155. Haase C, Stieler JT, Arendt T, Holzer M. Pseudophosphorylation of tau protein alters its ability for self-aggregation. *J Neurochem*. 2004; 88(6):1509–1520. [PubMed: 15009652]
156. Paudel HK. The regulatory Ser262 of microtubule-associated protein tau is phosphorylated by phosphorylase kinase. *J Biol Chem*. 1997; 272(3):1777–1785. [PubMed: 8999860]
157. Preuss U, Biernat J, Mandelkow EM, Mandelkow E. The 'jaws' model of tau-microtubule interaction examined in CHO cells. *J Cell Sci*. 1997; 110(Pt 6):789–800. [PubMed: 9099953]
158. Gartner U, Janke C, Holzer M, Vanmechelen E, Arendt T. Postmortem changes in the phosphorylation state of tau-protein in the rat brain. *Neurobiol Aging*. 1998; 19(6):535–543. [PubMed: 10192212]
159. Luna-Munoz J, Chavez-Macias L, Garcia-Sierra F, Mena R. Earliest stages of tau conformational changes are related to the appearance of a sequence of specific phospho-dependent tau epitopes in Alzheimer's disease. *J Alzheimer's Dis JAD*. 2007; 12(4):365–375.
160. Li T, Paudel HK. Glycogen synthase kinase 3beta phosphorylates Alzheimer's disease-specific Ser396 of microtubule-associated protein tau by a sequential mechanism. *Biochemistry*. 2006; 45(10):3125–3133.10.1021/bi051634r [PubMed: 16519507]
161. Porzig R, Singer D, Hoffmann R. Epitope mapping of mAbs AT8 and Tau5 directed against hyperphosphorylated regions of the human tau protein. *Biochem Biophys Res Commun*. 2007; 358(2):644–649.10.1016/j.bbrc.2007.04.187 [PubMed: 17499212]

162. Otvos L Jr, Feiner L, Lang E, Szendrei GI, Goedert M, Lee VM. Monoclonal antibody PHF-1 recognizes tau protein phosphorylated at serine residues 396 and 404. *J Neurosci Res.* 1994; 39(6):669–673.10.1002/jnr.490390607 [PubMed: 7534834]
163. Rankin CA, Sun Q, Gamblin TC. Pseudo-phosphorylation of tau at Ser202 and Thr205 affects tau filament formation. *Brain Res Mol Brain Res.* 2005; 138(1):84–93.10.1016/j.molbrainres.2005.04.012 [PubMed: 15913837]
164. Rankin CA, Sun Q, Gamblin TC. Tau phosphorylation by GSK-3 β promotes tangle-like filament morphology. *Molecul Neurodegen.* 2007; 2:12.10.1186/1750-1326-2-12
165. Connell JW, Gibb GM, Betts JC, Blackstock WP, Gallo J, Lovestone S, Hutton M, Anderton BH. Effects of FTDP-17 mutations on the in vitro phosphorylation of tau by glycogen synthase kinase 3 β identified by mass spectrometry demonstrate certain mutations exert long-range conformational changes. *FEBS Lett.* 2001; 493(1):40–44. [PubMed: 11278002]
166. Min SW, Cho SH, Zhou Y, Schroeder S, Haroutunian V, Seeley WW, Huang EJ, Shen Y, Masliah E, Mukherjee C, Meyers D, Cole PA, Ott M, Gan L. Acetylation of tau inhibits its degradation and contributes to tauopathy. *Neuron.* 2010; 67(6):953–966.10.1016/j.neuron.2010.08.044 [PubMed: 20869593]
167. Cohen TJ, Guo JL, Hurtado DE, Kwong LK, Mills IP, Trojanowski JQ, Lee VM. The acetylation of tau inhibits its function and promotes pathological tau aggregation. *Nature Commun.* 2011; 2:252.10.1038/ncomms1255 [PubMed: 21427723]
168. Cook C, Carlomagno Y, Gendron TF, Dunmore J, Scheffel K, Stetler C, Davis M, Dickson D, Jarpe M, DeTure M, Petrucelli L. Acetylation of the KXGS motifs in tau is a critical determinant in modulation of tau aggregation and clearance. *Hum Mol Genet.* 2014; 23(1):104–116.10.1093/hmg/ddt402 [PubMed: 23962722]
169. Ding H, Dolan PJ, Johnson GV. Histone deacetylase 6 interacts with the microtubule-associated protein tau. *J Neurochem.* 2008; 106(5):2119–2130.10.1111/j.1471-4159.2008.05564.x [PubMed: 18636984]
170. Cook C, Gendron TF, Scheffel K, Carlomagno Y, Dunmore J, DeTure M, Petrucelli L. Loss of HDAC6, a novel CHIP substrate, alleviates abnormal tau accumulation. *Hum Mol Genet.* 2012; 21(13):2936–2945.10.1093/hmg/dds125 [PubMed: 22492994]
171. Xiong Y, Zhao K, Wu J, Xu Z, Jin S, Zhang YQ. HDAC6 mutations rescue human tau-induced microtubule defects in *Drosophila*. *Proc Natl Acad Sci USA.* 2013; 110(12):4604–4609.10.1073/pnas.1207586110 [PubMed: 23487739]
172. Julien C, Tremblay C, Phivilay A, Berthiaume L, Emond V, Julien P, Calon F. High-fat diet aggravates amyloid-beta and tau pathologies in the 3xTg-AD mouse model. *Neurobiol Aging.* 2010; 31(9):1516–1531.10.1016/j.neurobiolaging.2008.08.022 [PubMed: 18926603]
173. Cohen TJ, Friedmann D, Hwang AW, Marmorstein R, Lee VM. The microtubule-associated tau protein has intrinsic acetyltransferase activity. *Nat Struct Mol Biol.* 2013; 20(6):756–762.10.1038/nsmb.2555 [PubMed: 23624859]
174. Kamah A, Huvent I, Cantrelle FX, Qi H, Lippens G, Landrieu I, Smet-Nocca C. Nuclear magnetic resonance analysis of the acetylation pattern of the neuronal Tau protein. *Biochemistry.* 2014; 53(18):3020–3032.10.1021/bi500006v [PubMed: 24708343]
175. Rissman RA, Poon WW, Blurton-Jones M, Oddo S, Torp R, Vitek MP, LaFerla FM, Rohn TT, Cotman CW. Caspase-cleavage of tau is an early event in Alzheimer disease tangle pathology. *J Clin Invest.* 2004; 114(1):121–130.10.1172/JCI20640 [PubMed: 15232619]
176. Basurto-Islas G, Luna-Munoz J, Guillozet-Bongaarts AL, Binder LI, Mena R, Garcia-Sierra F. Accumulation of aspartic acid421- and glutamic acid391-cleaved tau in neurofibrillary tangles correlates with progression in Alzheimer disease. *J Neuropathol Exp Neurol.* 2008; 67(5):470–483.10.1097/NEN.0b013e31817275c7 [PubMed: 18431250]
177. Ugolini G, Cattaneo A, Novak M. Co-localization of truncated tau and DNA fragmentation in Alzheimer's disease neurones. *NeuroReport.* 1997; 8(17):3709–3712. [PubMed: 9427355]
178. Cotman CW, Poon WW, Rissman RA, Blurton-Jones M. The role of caspase cleavage of tau in Alzheimer disease neuropathology. *J Neuropathol Exp Neurol.* 2005; 64(2):104–112. [PubMed: 15751224]

179. Gamblin TC, Chen F, Zambrano A, Abraha A, Lagalwar S, Guillozet AL, Lu M, Fu Y, Garcia-Sierra F, LaPointe N, Miller R, Berry RW, Binder LI, Cryns VL. Caspase cleavage of tau: linking amyloid and neurofibrillary tangles in Alzheimer's disease. *Proc Natl Acad Sci USA*. 2003; 100(17):10032–10037.10.1073/pnas.1630428100 [PubMed: 12888622]
180. Park SY, Ferreira A. The generation of a 17 kDa neurotoxic fragment: an alternative mechanism by which tau mediates beta-amyloid-induced neurodegeneration. *J Neurosci Off J Soc Neurosci*. 2005; 25(22):5365–5375.10.1523/JNEUROSCI.1125-05.2005
181. Kenessey A, Nacharaju P, Ko LW, Yen SH. Degradation of tau by lysosomal enzyme cathepsin D: implication for Alzheimer neurofibrillary degeneration. *J Neurochem*. 1997; 69(5):2026–2038. [PubMed: 9349548]
182. Arai T, Guo JP, McGeer PL. Proteolysis of non-phosphorylated and phosphorylated tau by thrombin. *J Biol Chem*. 2005; 280(7):5145–5153.10.1074/jbc.M409234200 [PubMed: 15542598]
183. Yang LS, Gordon-Krajcer W, Ksiezak-Reding H. Tau released from paired helical filaments with formic acid or guanidine is susceptible to calpain-mediated proteolysis. *J Neurochem*. 1997; 69(4):1548–1558. [PubMed: 9326284]
184. Ferreira A, Bigio EH. Calpain-mediated tau cleavage: a mechanism leading to neurodegeneration shared by multiple tauopathies. *Mol Med*. 2011; 17(7–8):676–685.10.2119/molmed.2010.00220 [PubMed: 21442128]
185. Garg S, Timm T, Mandelkow EM, Mandelkow E, Wang Y. Cleavage of Tau by calpain in Alzheimer's disease: the quest for the toxic 17 kD fragment. *Neurobiol Aging*. 2011; 32(1):1–14.10.1016/j.neurobiolaging.2010.09.008 [PubMed: 20961659]
186. Zhang Z, Song M, Liu X, Kang SS, Kwon IS, Duong DM, Seyfried NT, Hu WT, Liu Z, Wang JZ, Cheng L, Sun YE, Yu SP, Levey AI, Ye K. Cleavage of tau by asparagine endopeptidase mediates the neurofibrillary pathology in Alzheimer's disease. *Nat Med*. 2014; 20(11):1254–1262.10.1038/nm.3700 [PubMed: 25326800]
187. Takahashi M, Tsujioka Y, Yamada T, Tsuboi Y, Okada H, Yamamoto T, Liposits Z. Glycosylation of microtubule-associated protein tau in Alzheimer's disease brain. *Acta Neuropathol*. 1999; 97(6):635–641. [PubMed: 10378383]
188. Wang JZ, Grundke-Iqbal I, Iqbal K. Glycosylation of microtubule-associated protein tau: an abnormal posttranslational modification in Alzheimer's disease. *Nat Med*. 1996; 2(8):871–875. [PubMed: 8705855]
189. Kuhla B, Haase C, Flach K, Luth HJ, Arendt T, Munch G. Effect of pseudophosphorylation and cross-linking by lipid peroxidation and advanced glycation end product precursors on tau aggregation and filament formation. *J Biol Chem*. 2007; 282(10):6984–6991.10.1074/jbc.M609521200 [PubMed: 17082178]
190. Nacharaju P, Ko L, Yen SH. Characterization of in vitro glycation sites of tau. *J Neurochem*. 1997; 69(4):1709–1719. [PubMed: 9326300]
191. Bulbarelli A, Lonati E, Cazzaniga E, Gregori M, Masserini M. Pin1 affects Tau phosphorylation in response to Aβ oligomers. *Mol Cell Neurosci*. 2009; 42(1):75–80.10.1016/j.mcn.2009.06.001
192. Horiguchi T, Uryu K, Giasson BI, Ischiropoulos H, Lightfoot R, Bellmann C, Richter-Landsberg C, Lee VM, Trojanowski JQ. Nitration of tau protein is linked to neurodegeneration in tauopathies. *Am J Pathol*. 2003; 163(3):1021–1031.10.1016/S0002-9440(10)63462-1 [PubMed: 12937143]
193. Singer SM, Zainelli GM, Norlund MA, Lee JM, Muma NA. Transglutaminase bonds in neurofibrillary tangles and paired helical filament tau early in Alzheimer's disease. *Neurochem Int*. 2002; 40(1):17–30. [PubMed: 11738469]
194. Dorval V, Fraser PE. Small ubiquitin-like modifier (SUMO) modification of natively unfolded proteins tau and alpha-synuclein. *J Biol Chem*. 2006; 281(15):9919–9924.10.1074/jbc.M510127200 [PubMed: 16464864]
195. Schweers O, Mandelkow EM, Biernat J, Mandelkow E. Oxidation of cysteine-322 in the repeat domain of microtubule-associated protein tau controls the in vitro assembly of paired helical filaments. *Proc Natl Acad Sci USA*. 1995; 92(18):8463–8467. [PubMed: 7667312]

196. Arnaud LT, Myeku N, Figueiredo-Pereira ME. Proteasome-caspase-cathepsin sequence leading to tau pathology induced by prostaglandin J2 in neuronal cells. *J Neurochem.* 2009; 110(1):328–342.10.1111/j.1471-4159.2009.06142.x [PubMed: 19457109]
197. David DC, Layfield R, Serpell L, Narain Y, Goedert M, Spillantini MG. Proteasomal degradation of tau protein. *J Neurochem.* 2002; 83(1):176–185. [PubMed: 12358741]
198. Yu CH, Si T, Wu WH, Hu J, Du JT, Zhao YF, Li YM. O-GlcNAcylation modulates the self-aggregation ability of the fourth microtubule-binding repeat of tau. *Biochem Biophys Res Commun.* 2008; 375(1):59–62.10.1016/j.bbrc.2008.07.101 [PubMed: 18671940]
199. Liu F, Shi J, Tanimukai H, Gu J, Gu J, Grundke-Iqbal I, Iqbal K, Gong CX. Reduced O-GlcNAcylation links lower brain glucose metabolism and tau pathology in Alzheimer's disease. *Brain J Neurol.* 2009; 132(Pt 7):1820–1832.10.1093/brain/awp099
200. Necula M, Kuret J. Pseudophosphorylation and glycation of tau protein enhance but do not trigger fibrillization in vitro. *J Biol Chem.* 2004; 279(48):49694–49703.10.1074/jbc.M405527200 [PubMed: 15364924]
201. Ledesma MD, Medina M, Avila J. The in vitro formation of recombinant tau polymers: effect of phosphorylation and glycation. *Molecul Chem Neuropathol/Spons Int Soc Neurochem World Fed Neurol Res Groups Neurochem Cerebrospinal Fluid.* 1996; 27(3):249–258.
202. Reynolds MR, Berry RW, Binder LI. Site-specific nitration differentially influences tau assembly in vitro. *Biochemistry.* 2005; 44(42):13997–14009.10.1021/bi051028w [PubMed: 16229489]
203. Reynolds MR, Reyes JF, Fu Y, Bigio EH, Guillozet-Bongaarts AL, Berry RW, Binder LI. Tau nitration occurs at tyrosine 29 in the fibrillar lesions of Alzheimer's disease and other tauopathies. *J Neurosci Off J Soc Neurosci.* 2006; 26(42):10636–10645.10.1523/JNEUROSCI.2143-06.2006
204. Reyes JF, Reynolds MR, Horowitz PM, Fu Y, Guillozet-Bongaarts AL, Berry R, Binder LI. A possible link between astrocyte activation and tau nitration in Alzheimer's disease. *Neurobiol Dis.* 2008; 31(2):198–208.10.1016/j.nbd.2008.04.005 [PubMed: 18562203]
205. Takahashi K, Ishida M, Komano H, Takahashi H. SUMO-1 immunoreactivity co-localizes with phospho-Tau in APP transgenic mice but not in mutant Tau transgenic mice. *Neurosci Lett.* 2008; 441(1):90–93.10.1016/j.neulet.2008.06.012 [PubMed: 18586401]
206. Wang DS, Dickson DW, Malter JS. Tissue transglutaminase, protein cross-linking and Alzheimer's disease: review and views. *Int J Clin Exp Pathol.* 2008; 1(1):5–18. [PubMed: 18784819]
207. Appelt DM, Kopen GC, Boyne LJ, Balin BJ. Localization of transglutaminase in hippocampal neurons: implications for Alzheimer's disease. *J Histochem Cytochem Off J Histochem Soc.* 1996; 44(12):1421–1427.
208. Wilhelmus MM, de Jager M, Rozemuller AJ, Breve J, Bol JG, Eckert RL, Drukarch B. Transglutaminase 1 and its regulator tazarotene-induced gene 3 localize to neuronal tau inclusions in tauopathies. *J Pathol.* 2012; 226(1):132–142.10.1002/path.2984 [PubMed: 22009441]
209. Dou F, Netzer WJ, Tanemura K, Li F, Hartl FU, Takashima A, Gouras GK, Greengard P, Xu H. Chaperones increase association of tau protein with microtubules. *Proc Natl Acad Sci USA.* 2003; 100(2):721–726. [PubMed: 12522269]
210. Chen B, Piel WH, Gui L, Bruford E, Monteiro A. The HSP90 family of genes in the human genome: insights into their divergence and evolution. *Genomics.* 2005; 86(6):627–637.10.1016/j.ygeno.2005.08.012 [PubMed: 16269234]
211. Garnier C, Barbier P, Gilli R, Lopez C, Peyrot V, Briand C. Heat-shock protein 90 (hsp90) binds in vitro to tubulin dimer and inhibits microtubule formation. *Biochem Biophys Res Commun.* 1998; 250(2):414–419.10.1006/bbrc.1998.9319 [PubMed: 9753644]
212. Dickey CA, Eriksen J, Kamal A, Burrows F, Kasibhatla S, Eckman CB, Hutton M, Petrucelli L. Development of a high throughput drug screening assay for the detection of changes in tau levels—proof of concept with HSP90 inhibitors. *Curr Alzheimer Res.* 2005; 2(2):231–238. [PubMed: 15974923]
213. Dickey CA, Dunmore J, Lu B, Wang JW, Lee WC, Kamal A, Burrows F, Eckman C, Hutton M, Petrucelli L. HSP induction mediates selective clearance of tau phosphorylated at proline-

- directed Ser/Thr sites but not KXGS (MARK) sites. *Faseb J.* 2006; 20(6):753–755. [PubMed: 16464956]
214. Dickey CA, Kamal A, Lundgren K, Klosak N, Bailey RM, Dunmore J, Ash P, Shoraka S, Zlatkovic J, Eckman CB, Patterson C, Dickson DW, Nahman NS Jr, Hutton M, Burrows F, Petrucelli L. The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins. *J Clin Invest.* 2007; 117(3):648–658. [PubMed: 17304350]
 215. Luo W, Dou F, Rodina A, Chip S, Kim J, Zhao Q, Moulick K, Aguirre J, Wu N, Greengard P, Chiosis G. Roles of heat-shock protein 90 in maintaining and facilitating the neurodegenerative phenotype in tauopathies. *Proc Natl Acad Sci USA.* 2007; 104(22):9511–9516.10.1073/pnas.0701055104 [PubMed: 17517623]
 216. Tortosa E, Santa-Maria I, Moreno F, Lim F, Perez M, Avila J. Binding of Hsp90 to tau promotes a conformational change and aggregation of tau protein. *J Alzheimer's Dis JAD.* 2009; 17(2): 319–325.10.3233/JAD-2009-1049
 217. Karagoz GE, Duarte AM, Akoury E, Ippel H, Biernat J, Moran Luengo T, Radli M, Didenko T, Nordhues BA, Veprintsev DB, Dickey CA, Mandelkow E, Zweckstetter M, Boelens R, Madl T, Rudiger SG. Hsp90-Tau complex reveals molecular basis for specificity in chaperone action. *Cell.* 2014; 156(5):963–974.10.1016/j.cell.2014.01.037 [PubMed: 24581495]
 218. Jinwal UK, Koren J 3rd, Borysov SI, Schmid AB, Abisambra JF, Blair LJ, Johnson AG, Jones JR, Shults CL, O'Leary JC 3rd, Jin Y, Buchner J, Cox MB, Dickey CA. The Hsp90 cochaperone, FKBP51, increases Tau stability and polymerizes microtubules. *J Neurosci Off J Soc Neurosci.* 2010; 30(2):591–599.10.1523/JNEUROSCI.4815-09.2010
 219. Blair LJ, Nordhues BA, Hill SE, Scaglione KM, O'Leary JC 3rd, Fontaine SN, Breydo L, Zhang B, Li P, Wang L, Cotman C, Paulson HL, Muschol M, Uversky VN, Klengel T, Binder EB, Kaye R, Golde TE, Berchtold N, Dickey CA. Accelerated neurodegeneration through chaperone-mediated oligomerization of tau. *J Clin Invest.* 2013; 123(10):4158–4169.10.1172/JCI69003 [PubMed: 23999428]
 220. Chambraud B, Sardin E, Giustiniani J, Dounane O, Schumacher M, Goedert M, Baulieu EE. A role for FKBP52 in Tau protein function. *Proc Natl Acad Sci USA.* 2010; 107(6):2658–2663.10.1073/pnas.0914957107 [PubMed: 20133804]
 221. Jinwal UK, Trotter JH, Abisambra JF, Koren J 3rd, Lawson LY, Vestal GD, O'Leary JC 3rd, Johnson AG, Jin Y, Jones JR, Li Q, Weeber EJ, Dickey CA. The Hsp90 kinase co-chaperone Cdc37 regulates tau stability and phosphorylation dynamics. *J Biol Chem.* 2011; 286(19):16976–16983.10.1074/jbc.M110.182493 [PubMed: 21367866]
 222. Gong CX, Liu F, Wu G, Rossie S, Wegiel J, Li L, Grundke-Iqbal I, Iqbal K. Dephosphorylation of microtubule-associated protein tau by protein phosphatase 5. *J Neurochem.* 2004; 88(2):298–310. [PubMed: 14690518]
 223. Liu F, Iqbal K, Grundke-Iqbal I, Rossie S, Gong CX. Dephosphorylation of tau by protein phosphatase 5: impairment in Alzheimer's disease. *J Biol Chem.* 2005; 280(3):1790–1796.10.1074/jbc.M410775200 [PubMed: 15546861]
 224. Young JC, Agashe VR, Siegers K, Hartl FU. Pathways of chaperone-mediated protein folding in the cytosol. *Nat Rev Mol Cell Biol.* 2004; 5(10):781–791.10.1038/nrm1492 [PubMed: 15459659]
 225. Shimura H, Schwartz D, Gygi SP, Kosik KS. CHIP-Hsc70 complex ubiquitinates phosphorylated tau and enhances cell survival. *J Biol Chem.* 2004; 279(6):4869–4876. [PubMed: 14612456]
 226. Jinwal UK, Akoury E, Abisambra JF, O'Leary JC 3rd, Thompson AD, Blair LJ, Jin Y, Bacon J, Nordhues BA, Cockman M, Zhang J, Li P, Zhang B, Borysov S, Uversky VN, Biernat J, Mandelkow E, Gestwicki JE, Zweckstetter M, Dickey CA. Imbalance of Hsp70 family variants fosters tau accumulation. *FASEB J Off Publ Fed Am Soc Exp Biol.* 2013; 27(4):1450–1459.10.1096/fj.12-220889
 227. Sarkar M, Kuret J, Lee G. Two motifs within the tau microtubule-binding domain mediate its association with the hsc70 molecular chaperone. *J Neurosci Res.* 2008; 86(12):2763–2773.10.1002/jnr.21721 [PubMed: 18500754]
 228. Jinwal UK, O'Leary JC 3rd, Borysov SI, Jones JR, Li Q, Koren J 3rd, Abisambra JF, Vestal GD, Lawson LY, Johnson AG, Blair LJ, Jin Y, Miyata Y, Gestwicki JE, Dickey CA. Hsc70 rapidly

- engages tau after microtubule destabilization. *J Biol Chem.* 2010; 285(22):16798–16805.10.1074/jbc.M110.113753 [PubMed: 20308058]
229. Petrucelli L, Dickson D, Kehoe K, Taylor J, Snyder H, Grover A, De Lucia M, McGowan E, Lewis J, Prihar G, Kim J, Dillmann WH, Browne SE, Hall A, Voellmy R, Tsuboi Y, Dawson TM, Wolozin B, Hardy J, Hutton M. CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation. *Hum Mol Genet.* 2004; 13(7):703–714.10.1093/hmg/ddh083 [PubMed: 14962978]
 230. Elliott E, Laufer O, Ginzburg I. BAG-1M is up-regulated in hippocampus of Alzheimer's disease patients and associates with tau and APP proteins. *J Neurochem.* 2009; 109(4):1168–1178.10.1111/j.1471-4159.2009.06047.x [PubMed: 19317853]
 231. Elliott E, Tsvetkov P, Ginzburg I. BAG-1 associates with Hsc70.Tau complex and regulates the proteasomal degradation of tau protein. *J Biol Chem.* 2007; 282(51):37276–37284.10.1074/jbc.M706379200 [PubMed: 17954934]
 232. Carrettiero DC, Hernandez I, Neveu P, Papagiannakopoulos T, Kosik KS. The cochaperone BAG2 sweeps paired helical filament- insoluble tau from the microtubule. *J Neurosci Off J Soc Neurosci.* 2009; 29(7):2151–2161.10.1523/JNEUROSCI.4660-08.2009
 233. Patterson KR, Ward SM, Combs B, Voss K, Kanaan NM, Morfini G, Brady ST, Gamblin TC, Binder LI. Heat shock protein 70 prevents both tau aggregation and the inhibitory effects of preexisting tau aggregates on fast axonal transport. *Biochemistry.* 2011; 50(47):10300–10310.10.1021/bi2009147 [PubMed: 22039833]
 234. Voss K, Combs B, Patterson KR, Binder LI, Gamblin TC. Hsp70 alters tau function and aggregation in an isoform specific manner. *Biochemistry.* 2012; 51(4):888–898.10.1021/bi2018078 [PubMed: 22236337]
 235. Patterson KR, Remmers C, Fu Y, Brooker S, Kanaan NM, Vana L, Ward S, Reyes JF, Philibert K, Glucksman MJ, Binder LI. Characterization of prefibrillar Tau oligomers in vitro and in Alzheimer disease. *J Biol Chem.* 2011; 286(26):23063–23076.10.1074/jbc.M111.237974 [PubMed: 21550980]
 236. Miyata Y, Li X, Lee HF, Jinwal UK, Srinivasan SR, Seguin SP, Young ZT, Brodsky JL, Dickey CA, Sun D, Gestwicki JE. Synthesis and initial evaluation of YM-08, a blood-brain barrier permeable derivative of the heat shock protein 70 (Hsp70) inhibitor MKT-077, which reduces tau levels. *ACS Chem Neurosci.* 2013; 4(6):930–939.10.1021/cn300210g [PubMed: 23472668]
 237. Abisambra J, Jinwal UK, Miyata Y, Rogers J, Blair L, Li X, Seguin SP, Wang L, Jin Y, Bacon J, Brady S, Cockman M, Guidi C, Zhang J, Koren J, Young ZT, Atkins CA, Zhang B, Lawson LY, Weeber EJ, Brodsky JL, Gestwicki JE, Dickey CA. Allosteric heat shock protein 70 inhibitors rapidly rescue synaptic plasticity deficits by reducing aberrant tau. *Biol Psychiatry.* 2013; 74(5):367–374.10.1016/j.biopsych.2013.02.027 [PubMed: 23607970]
 238. Wilhelmus MM, Otte-Holler I, Wesseling P, de Waal RM, Boelens WC, Verbeek MM. Specific association of small heat shock proteins with the pathological hallmarks of Alzheimer's disease brains. *Neuropathol Appl Neurobiol.* 2006; 32(2):119–130.10.1111/j.1365-2990.2006.00689.x [PubMed: 16599941]
 239. Shimura H, Miura-Shimura Y, Kosik KS. Binding of tau to heat shock protein 27 leads to decreased concentration of hyperphosphorylated tau and enhanced cell survival. *J Biol Chem.* 2004; 279(17):17957–17962.10.1074/jbc.M400351200 [PubMed: 14963027]
 240. Abisambra JF, Blair LJ, Hill SE, Jones JR, Kraft C, Rogers J, Koren J 3rd, Jinwal UK, Lawson L, Johnson AG, Wilcock D, O'Leary JC, Jansen-West K, Muschol M, Golde TE, Weeber EJ, Banko J, Dickey CA. Phosphorylation dynamics regulate Hsp27-mediated rescue of neuronal plasticity deficits in tau transgenic mice. *J Neurosci Off J Soc Neurosci.* 2010; 30(46):15374–15382.10.1523/JNEUROSCI.3155-10.2010
 241. Wang S, Toth ME, Bereczki E, Santha M, Guan ZZ, Winblad B, Pei JJ. Interplay between glycogen synthase kinase-3beta and tau in the cerebellum of Hsp27 transgenic mouse. *J Neurosci Res.* 2011; 89(8):1267–1275.10.1002/jnr.22660 [PubMed: 21544852]
 242. Renkawek K, Bosman GJ, de Jong WW. Expression of small heat-shock protein hsp 27 in reactive gliosis in Alzheimer disease and other types of dementia. *Acta Neuropathol.* 1994; 87(5):511–519. [PubMed: 8059604]

243. Renkawek K, Voorter CE, Bosman GJ, van Workum FP, de Jong WW. Expression of alpha B-crystallin in Alzheimer's disease. *Acta Neuropathol.* 1994; 87(2):155–160. [PubMed: 8171966]
244. Bjorkdahl C, Sjogren MJ, Zhou X, Concha H, Avila J, Winblad B, Pei JJ. Small heat shock proteins Hsp27 or alphaB-crystallin and the protein components of neurofibrillary tangles: tau and neurofilaments. *J Neurosci Res.* 2008; 86(6):1343–1352.10.1002/jnr.21589 [PubMed: 18061943]
245. Dabir DV, Trojanowski JQ, Richter-Landsberg C, Lee VM, Forman MS. Expression of the small heat-shock protein alphaB-crystallin in tauopathies with glial pathology. *Am J Pathol.* 2004; 164(1):155–166. [PubMed: 14695329]
246. Lopez-Gonzalez I, Carmona M, Arregui L, Kovacs GG, Ferrer I. alphaB-crystallin and HSP27 in glial cells in tauopathies. *Neuropathol Off J Japn Soc Neuropathol.* 201410.1111/neup.12134
247. Aaltonen T, Adelman J, Akimoto T, Alvarez Gonzalez B, Amerio S, Amidei D, Anastassov A, Annovi A, Antos J, Apollinari G, Apresyan A, Arisawa T, Artikov A, Ashmanskas W, Attal A, Aurisano A, Azfar F, Badgett W, Barbaro-Galtieri A, Barnes VE, Barnett BA, Barria P, Bartos P, Bartsch V, Bauer G, Beauchemin PH, Bedeschi F, Beecher D, Behari S, Bellettini G, Bellinger J, Benjamin D, Beretvas A, Beringer J, Bhatti A, Binkley M, Bisello D, Bizjak I, Blair RE, Blocker C, Blumenfeld B, Bocci A, Bodek A, Boisvert V, Bolla G, Bortoletto D, Boudreau J, Boveia A, Brau B, Bridgeman A, Brigliadori L, Bromberg C, Brubaker E, Budagov J, Budd HS, Budd S, Burke S, Burkett K, Busetto G, Bussey P, Buzatu A, Byrum KL, Cabrera S, Calancha C, Campanelli M, Campbell M, Canelli F, Canepa A, Carls B, Carlsmith D, Carosi R, Carrillo S, Carron S, Casal B, Casarsa M, Castro A, Catastini P, Cauz D, Cavaliere V, Cavalli-Sforza M, Cerri A, Cerrito L, Chang SH, Chen YC, Chertok M, Chiarelli G, Chlachidze G, Chlebana F, Cho K, Chokheli D, Chou JP, Choudalakis G, Chuang SH, Chung K, Chung WH, Chung YS, Chwalek T, Ciobanu CI, Ciocci MA, Clark A, Clark D, Compostella G, Convery ME, Conway J, Cordelli M, Cortiana G, Cox CA, Cox DJ, Crescioli F, Cuenca Almenar C, Cuevas J, Culbertson R, Cully JC, Dagenhart D, Datta M, Davies T, de Barbaro P, De Cecco S, Deisher A, De Lorenzo G, Dell'Orso M, Deluca C, Demortier L, Deng J, Deninno M, Derwent PF, Di Canto A, di Giovanni GP, Dionisi C, Di Ruzza B, Dittmann JR, D'Onofrio M, Donati S, Dong P, Donini J, Dorigo T, Dube S, Efron J, Elagin A, Erbacher R, Errede D, Errede S, Eusebi R, Fang HC, Farrington S, Fedorko WT, Feild RG, Feindt M, Fernandez JP, Ferrazza C, Field R, Flanagan G, Forrest R, Frank MJ, Franklin M, Freeman JC, Furic I, Gallinaro M, Galyard J, Garberson F, Garcia JE, Garfinkel AF, Garosi P, Genser K, Gerberich H, Gerdes D, Gessler A, Giagu S, Giakoumopoulou V, Giannetti P, Gibson K, Gimmell JL, Ginsburg CM, Giokaris N, Giordani M, Giromini P, Giunta M, Giurgiu G, Glagolev V, Glenzinski D, Gold M, Goldschmidt N, Golossanov A, Gomez G, Gomez-Ceballos G, Goncharov M, Gonzalez O, Gorelov I, Goshaw AT, Goulianos K, Gresele A, Grinstein S, Grosso-Pilcher C, Group RC, Grundler U, Guimaraes da Costa J, Gunay-Unalan Z, Haber C, Hahn K, Hahn SR, Halkiadakis E, Han BY, Han JY, Happacher F, Hara K, Hare D, Hare M, Harper S, Harr RF, Harris RM, Hartz M, Hatakeyama K, Hays C, Heck M, Heijboer A, Heinrich J, Henderson C, Herndon M, Heuser J, Hewamanage S, Hidas D, Hill CS, Hirschbuehl D, Hocker A, Hou S, Houlden M, Hsu SC, Huffman BT, Hughes RE, Husemann U, Hussein M, Huston J, Incandela J, Introzzi G, Iori M, Ivanov A, James E, Jang D, Jayatilaka B, Jeon EJ, Jha MK, Jindariani S, Johnson W, Jones M, Joo KK, Jun SY, Jung JE, Junk TR, Kamon T, Kar D, Karchin PE, Kato Y, Kephart R, Ketchum W, Keung J, Khotilovich V, Kilminster B, Kim DH, Kim HS, Kim HW, Kim JE, Kim MJ, Kim SB, Kim SH, Kim YK, Kimura N, Kirsch L, Klimenko S, Knuteson B, Ko BR, Kondo K, Kong DJ, Konigsberg J, Korytov A, Kotwal AV, Kreps M, Kroll J, Krop D, Krumnack N, Kruse M, Krutelyov V, Kubo T, Kuhr T, Kulkarni NP, Kurata M, Kwang S, Laasanen AT, Lami S, Lammel S, Lancaster M, Lander RL, Lannon K, Lath A, Latino G, Lazzizzera I, LeCompte T, Lee E, Lee HS, Lee SW, Leone S, Lewis JD, Lin CS, Linacre J, Lindgren M, Lipeles E, Lister A, Litvintsev DO, Liu C, Liu T, Lockyer NS, Loginov A, Loreti M, Lovas L, Lucchesi D, Luci C, Lueck J, Lujan P, Lukens P, Lungu G, Lyons L, Lys J, Lysak R, MacQueen D, Madrak R, Maeshima K, Makhoul K, Maki T, Maksimovic P, Malde S, Malik S, Manca G, Manousakis-Katsikakis A, Margaroli F, Marino C, Marino CP, Martin A, Martin V, Martinez M, Martinez-Ballarín R, Maruyama T, Mastrandrea P, Masubuchi T, Mathis M, Mattson ME, Mazzanti P, McFarland KS, McIntyre P, McNulty R, Mehta A, Mehtala P, Menzione A, Merkel P, Mesropian C, Miao T, Miladinovic N, Miller R, Mills C, Milnik M, Mitra A, Mitselmakher G, Miyake H, Moggi N, Mondragon MN, Moon CS, Moore R, Morello MJ, Morlock J, Movilla Fernandez P, Mulmenstadt J, Mukherjee

A, Muller T, Mumford R, Murat P, Mussini M, Nachtman J, Nagai Y, Nagano A, Naganoma J, Nakamura K, Nakano I, Napier A, Necula V, Nett J, Neu C, Neubauer MS, Neubauer S, Nielsen J, Nodulman L, Norman M, Norniella O, Nurse E, Oakes L, Oh SH, Oh YD, Oksuzian I, Okusawa T, Orava R, Osterberg K, Pagan Griso S, Pagliarone C, Palencia E, Papadimitriou V, Papaikonomou A, Paramonov AA, Parks B, Pashapour S, Patrick J, Pauletta G, Paulini M, Paus C, Peiffer T, Pellett DE, Penzo A, Phillips TJ, Piacentino G, Pianori E, Pinera L, Pitts K, Plager C, Pondrom L, Poukhov O, Pounder N, Prakoshyn F, Pronko A, Proudfoot J, Ptohos F, Pueschel E, Punzi G, Pursley J, Rademacker J, Rahaman A, Ramakrishnan V, Ranjan N, Redondo I, Renton P, Renz M, Rescigno M, Richter S, Rimondi F, Ristori L, Robson A, Rodrigo T, Rodriguez T, Rogers E, Rolli S, Roser R, Rossi M, Rossin R, Roy P, Ruiz A, Russ J, Rusu V, Rutherford B, Saarikko H, Safonov A, Sakumoto WK, Salto O, Santi L, Sarkar S, Sartori L, Sato K, Savoy-Navarro A, Schlabach P, Schmidt A, Schmidt EE, Schmidt MA, Schmidt MP, Schmitt M, Schwarz T, Scodellaro L, Scribano A, Scuri F, Sedov A, Seidel S, Seiya Y, Semenov A, Sexton-Kennedy L, Sforza F, Sfyrta A, Shalhout SZ, Shears T, Shepard PF, Shimojima M, Shiraishi S, Shochet M, Shon Y, Shreyber I, Sinervo P, Sisakyan A, Slaughter AJ, Slaunwhite J, Sliwa K, Smith JR, Snider FD, Snihur R, Soha A, Somalwar S, Sorin V, Spreitzer T, Squillacioti P, Stanitzki M, St Denis R, Stelzer B, Stelzer-Chilton O, Stentz D, Strologas J, Strycker GL, Suh JS, Sukhanov A, Suslov I, Suzuki T, Taffard A, Takashima R, Takeuchi Y, Tanaka R, Tecchio M, Teng PK, Terashi K, Thom J, Thompson AS, Thompson GA, Thomson E, Tipton P, Ttito-Guzman P, Tkaczyk S, Toback D, Tokar S, Tollefson K, Tomura T, Tonelli D, Torre S, Torretta D, Totaro P, Tourneur S, Trovato M, Tsai SY, Tu Y, Turini N, Ukegawa F, Vallecorsa S, van Remortel N, Varganov A, Vataga E, Vazquez F, Velev G, Vellidis C, Vidal M, Vidal R, Vila I, Vilar R, Vine T, Vogel M, Volobouev I, Volpi G, Wagner P, Wagner RG, Wagner RL, Wagner W, Wagner-Kuhr J, Wakisaka T, Wallny R, Wang SM, Warburton A, Waters D, Weinberger M, Weinelt J, Wester WC 3rd, Whitehouse B, Whiteson D, Wicklund AB, Wicklund E, Wilbur S, Williams G, Williams HH, Wilson P, Winer BL, Wittich P, Wolbers S, Wolfe C, Wright T, Wu X, Wurthwein F, Xie S, Yagil A, Yamamoto K, Yamaoka J, Yang UK, Yang YC, Yao WM, Yeh GP, Yi K, Yoh J, Yorita K, Yoshida T, Yu GB, Yu I, Yu SS, Yun JC, Zanello L, Zanetti A, Zhang X, Zheng Y, Zucchelli S, Collaboration CDF. Search for Higgs bosons predicted in two-Higgs-doublet models via decays to tau lepton pairs in 1.96 TeV pp collisions. *Phys Rev Lett.* 2009; 103(20):201801. [PubMed: 20365975]

248. Dammer EB, Lee AK, Duong DM, Gearing M, Lah JJ, Levey AI, Seyfried NT. Quantitative phosphoproteomics of alzheimer's disease reveals crosstalk between kinases and small heat shock proteins. *Proteomics.* 2014;10.1002/pmic.201400189

Fig. 1. Schematic diagram of the longest isoform of human tau and the locations of post-translational modifications important for aggregation relative to important protein domains. Pro-aggregation peptides 275–280 and 306–311 [83] are shown for comparison

Table 1Effects of *MAPT* mutation on tau aggregation

Mutation	Effect on aggregation	Associated Tauopathy	Reference
R5L	Increases tau aggregation	PSP	[18, 19]
R406W	Increases aggregation of tau reduces the binding of tau to MTs	FTDP-17	[20–30]
	Increased pS202 levels (increased aggregation)	AD	[31–36]
P301L	Increases aggregation of tau reduces the binding of tau to MTs	FTDP-17	[5, 18, 24–27, 30, 40–56]
	Increased pS202 levels (increased aggregation)		
P301S	Increases aggregation of tau reduces the binding of tau to MTs	FTDP-17	[57–62]
G272 V	Increases aggregation of tau reduces the binding of tau to MTs	FTDP-17	[18, 20, 24–26, 30, 63–66]
	Increased pS202 levels (increased aggregation)	Pick's disease	
V337M	Increases aggregation of tau reduces the binding of tau to MTs	FTDP-17	[18, 20, 21, 27]
	Increased pS202 levels (increased aggregation)		
K280	Increases aggregation of tau reduces the binding of tau to MTs	FTDP-17	[27, 46]
G335V	Increases aggregation of tau reduces the binding of tau to MTs	FTDP-17	[67]
N279K	Increases tau aggregation. reduces the binding of 4Rtau but not 3Rtau to MTs.	FTDP-17	[38, 68]
N296	Increases aggregation of tau reduces the binding of tau to MTs	Parkinson's disease, PSP	[69]
G303V	Increases tau aggregation	PSP	[70]
	Increases the binding of tau to MTs		
Exon 10+3 (IVS10+3G > A)	Increases tau aggregation reduces the binding of 4Rtau to MTs	FTDP-17	[71]
Exon 10+14 (IVS10+14C > T)	Increases tau aggregation	FTDP-17	[38]
N296H	Increases aggregation of tau reduces the binding of tau to microtubules	FTDP-17	[72]
I260V	Increases aggregation of tau reduces the binding of tau to MTs	FTDP-17	[73]
L266V	Increases aggregation of tau	Pick's disease	[74]
	Reduces the binding of tau to MTs		[75]
R5K	Increases aggregation of tau reduces the binding of tau to MTs	FTDP-17	[76]
Exon 10+12 (IVS10+12C > T)	Increases aggregation of tau	FTDP-17	[77, 78]
Exon 10+13 (IVS10+13A > G)	Increases aggregation of tau	FTDP-17	[24, 79]